

Subject Index

Review

<i>Biochemical bone markers, general</i>	93, 809, 842, 959, 1018, 1070, 1076, 1311, 1462
alkaline phosphatase isoenzymes.....	861, 960
pyridinium crosslinks.....	161, 1443

Pyrilinks®-D (Deoxypyridinoline crosslinks [Dpd] EIA)

see also *Pyrilinks, Pyridinium crosslinks by HPLC*

<i>animal model studies</i>	899, 900, 1115, 1117, 1119, 1120, 1140, 1142
-----------------------------------	--

biological variation

age.....	197
circadian (diurnal, nyctohemeral).....	912, 1019, 1464
correlation of urine collection methods.....	912, 1320
day to day.....	529, 912, 1132, 1135, 1464
ethnicity, race.....	1186
exercise, bed rest.....	1567
<i>comparison between methods</i>	197, 509, 962, 1056, 1524
<i>genetic influence, receptor gene polymorphisms</i>	1028, 1151, 1581
<i>method</i>	197
automated.....	1131, 1191
radioimmunoassay.....	1284
<i>performance characteristics</i>	197, 962, 1464
<i>photosensitivity</i>	800
<i>specificity</i>	197, 962, 1004

treatment effects

androgens.....	791, 1572
bisphosphonates	
alendronate.....	1057, 1464
etidronate.....	845, 907, 1056
pamidronate.....	608, 798, 853, 906, 916, 1512
other.....	918, 1129, 1453, 1512
calcitonin.....	1318
calcium.....	1319
cancer therapy.....	1512
corticosteroids.....	967, 1082, 1290, 1291, 1388
DMARDs (antirheumatic therapy).....	1217
gonadotropin-releasing hormone (GnRH) analogs.....	1344
growth hormone (GH).....	916, 1019, 1188
hormone replacement therapy (HRT).....	792, 798, 902, 907, 919, 967, 1020, 1058, 1129, 1135, 1188, 1581
insulin-like growth factor I (IGF-I).....	1019, 1188
parathyroid hormone (PTH).....	1445
SERMs (estrogen analogs).....	919
thyroid disorder therapy.....	1105, 1473
tibolone.....	1267
transplantation, renal.....	1064
vitamin D/metabolites.....	1319, 1388

values in

cancer	
breast.....	197, 963, 1203, 1397
multiple myeloma.....	772, 1452
prostate.....	1476
other.....	186, 538, 1091, 1137, 1512
children.....	197, 962, 1396, 1444, 1542
men.....	187, 791
nonskeletal disorders, other.....	1178, 1523
osteoporosis, osteopenia.....	197, 798, 904, 1057, 1407
fracture.....	1045, 1100, 1113
Paget's disease.....	197, 789, 798, 845, 1056, 1453
parathyroid disorders.....	197, 962, 1064, 1091
renal dysfunction or transplant.....	197, 1064
rheumatoid arthritis.....	1217, 1413, 1444
thyroid disorders.....	798, 1067, 1105, 1391, 1473, 1504

Pyrilinks-D continued*values in* continued

women

elderly.....	1113, 1407
peri- and/or postmenopausal.....	197, 509, 798, 1413, 1466
surgically-induced	1058
pregnancy, lactation	805
premenopausal.....	197, 509, 798, 1113, 1413

Pyrilinks[®] (Pyridinium crosslinks: Pyridinoline [Pyd] & Deoxypyridinoline [Dpd] EIA)*see also* *Pyridinium crosslinks by HPLC**animal model studies*.....411, 504, 506, 733, 788, 813, 988, 1068, 1069, 1118, 1120, 1562*biological variation*

age	372, 480, 553, 917, 934
circadian (diurnal, nyctohemeral).....	698, 912, 1492
correlation of urine collection methods.....	912, 940
day to day.....	394, 529, 912, 1019, 1135
ethnicity, race.....	1510
puberty	480

comparison between methods.....372, 394, 534, 553, 696, 789, 917, 962, 1050*distribution in urine*.....196, 394*genetic influence, receptor gene polymorphisms*.....898, 1482*method*.....196, 372, 394, 1050*performance characteristics*.....181, 372, 394, 696, 1050*photosensitivity*.....800*specificity*.....394, 962, 1050*treatment effects*

androgens.....791, 1572

antiepileptics.....794

bisphosphonates

alendronate.....675, 719, 878

etidronate.....845, 1336

pamidronate.....332, 372

other.....181, 561, 845, 1179, 1492

calcitonin.....698, 1541, 1580

calcium 698, 919, 1061, 1319 |

cancer therapy.....1204

corticosteroids.....846, 1290

gonadotrophin-releasing hormone (GnRH) analogs.....991, 1344

growth hormone (GH).....535, 901, 1019, 1481, 1541, 1580

hormone replacement therapy (HRT).....534, 792, 840, 902, 919, 1050, 1061, 1135, 1418, 1477

dosage adjustment.....766

insulin-like growth factor I (IGF-I).....203, 1019

parathyroid hormone (PTH).....991

SERMs (estrogen analogs).....919, 1150, 1418

transplantation, heart or renal.....913, 1064, 1350, 1390

thyroid disorder therapy.....332, 378, 561

tibolone 1267 |

vitamin D/metabolites.....840, 1319

values in

cancer

breast.....917

multiple myeloma.....695, 1204

prostate.....1086

other.....186, 538, 964

children 962 |

infants.....934

glucocorticoid excess.....917

men 372, 553, 561, 696, 791, 917, 940, 1050, 1293 |

elderly.....182, 372, 696

nonskeletal disorders, other.....199, 818, 846, 1353, 1523

osteoarthritis.....966

osteoporosis.....553, 675, 719, 878, 940, 1050, 1336, 1407

drug-induced.....940, 1050

Pyrilinks Continued

values in continued

Paget's disease.....	372, 789, 845, 858, 878, 917, 940, 1050, 1179
parathyroid disorders.....	917, 962, 1050, 1064
renal dysfunction or transplant.....	917, 1064, 1350
rheumatoid arthritis.....	989, 1413
thyroid disorders.....	378, 917, 1050, 1067
women.....	182, 550, 917, 940
elderly.....	182, 372, 696, 917, 980, 1293, 1407
peri- and/or postmenopausal.....	372, 553, 980, 1050, 1336, 1466
surgically-induced	766, 1050
premenopausal.....	372, 696, 719, 1050

Pyridinium crosslinks by HPLC (of Pyd & Dpd) and other methods

animal model studies 118, 121, 150, 381, 548, 555, 556, 557, 803, 974, 976, 1120, 1121, 1141, 1142, 1561, 1563, 1564

biological variation

age.....	119, 131, 137, 468, 480, 481, 487, 876, 1161
circadian (diurnal, nyctohemeral).....	130, 131, 158, 370, 445, 625, 736, 777
circannual, seasonal.....	1536
day to day.....	370, 494, 529, 777, 815, 1027, 1135
diet.....	484, 494, 1007, 1507
ethnicity, race.....	468, 1424
exercise , bed rest.....	354, 405, 477, 736, 1575
longitudinal.....	141, 407, 1472
menstrual cycle.....	928
puberty.....	480

distribution

in tissues.....	132, 133, 136, 161, 487, 496, 803, 1081, 1181, 1530
in urine (ratio of free to total).....	137, 196, 370, 394, 458, 459, 696, 798, 962, 1004

genetic influence, receptor gene polymorphisms.....1071, 1515

method.....89, 120, 132, 133, 136, 164, 165, 198, 490, 1147, 1284, 1434, 1524

 internal standard.....377, 490, 494, 958

photosensitivity.....132, 436, 800, 965, 1546

serum, plasma, perspiration557, 873, 874, 935, 1136, 1198, 1434

specificity (tissue)161, 803, 1004

 correlation to bone biopsy.....128, 915

 correlation to radioisotope kinetics.....129, 1446

stability.....815, 965, 1027

treatment effects

androgens.....1509

antiepileptics.....472, 1534

bisphosphonates

 alendronate.....326, 408, 446, 719, 970, 971, 1023, 1029, 1053, 1456, 1537

 etidronate.....845, 1056

 pamidronate.....608, 798, 885, 1130, 1345, 1422

 other.....154, 161, 164, 373, 1065, 1179, 1317, 1540, 1545

calcitonin.....373, 388, 544, 697, 1023, 1094, 1097

calcium.....625, 732, 919, 1007, 1008, 1157, 1544

cancer therapy.....653, 1176, 1296, 1345, 1516, 1540, 1545

corticosteroids.....768, 855, 925, 990, 1034, 1162

endocrine disorder therapy, other.....1509

growth hormone (GH).....71, 89, 440, 875, 1043, 1328, 1533

hormone replacement therapy (HRT).....141, 161, 165, 407, 466, 492, 493, 534, 792, 798, 919, 925, 1042,

.....1135, 1158

insulin-like growth factor I (IGF-I).....933, 1043

parathyroid disorder therapy.....61, 161, 869, 945, 946

parathyroid hormone (PTH).....388

SERMs (estrogen analogs).....653, 919, 1014, 1431

thyroid disorder therapy.....60, 161, 662, 751, 11473

transplantation, cardiac.....1422, 1438

vitamin D/metabolites.....1008

values in

cancer

 breast.....149, 197, 653, 1545

Pyridinium Crosslinks Continued

values in continued

cancer continued

multiple myeloma.....	1065, 1540
prostate.....	474, 1044, 1296, 1297
other.....	124, 126, 391, 682, 760, 983, 1091, 1176, 1516
children	88, 89, 481, 496, 678, 781, 875, 876, 962, 1161, 1542
diabetes	1412
fracture, traumatic.....	147, 854
growth disorders.....	71, 781, 875
men.....	88, 138, 391, 553, 696, 732
elderly.....	1293
mineral metabolism disorders, other.....	154
nonskeletal disorders, other.....	151, 199, 404, 496, 1012
osteoarthritis.....	120, 157, 160, 769, 770, 771, 783, 877, 1002, 1075, 1181
osteoarthrosis.....	1005
osteoporosis, osteopenic	88, 89, 101, 128, 147, 159, 161, 197, 388, 472, 493, 553, 656, 705, 719, 798, 936, 1045, 1090, 1094, 1100, 1456, 1472
Paget's disease.....	88, 89, 120, 154, 161, 164, 197, 373, 798, 845, 885, 1056, 1130
parathyroid disorders.....	61, 137, 154, 161, 164, 197, 939, 945, 962, 1008, 1091
renal dysfunction.....	197, 777, 1075
rheumatoid arthritis.....	122, 137, 138, 157, 160, 768, 771, 783, 925, 1075, 1162, 1413
synovial fluid.....	783, 877, 1181, 1362
spinal cord injury.....	897, 951
thyroid disorders.....	60, 464, 472, 798, 1324, 1448, 1472
women	
elderly.....	696, 1055, 1293, 1472
peri- or postmenopausal.....	101, 138, 141, 159, 161, 163, 164, 165, 391, 457, 472, 493, 509, 553, 705, 696, 726, 798, 936, 1055, 1077, 1090, 1096, 1159, 1413, 1472, 1532
surgically-induced	407, 492, 1036, 1521
pregnancy, lactation.....	699, 1092
premenopausal.....	88, 138, 141, 159, 161, 164, 165, 391, 472, 696, 719, 726, 798, 936, 1077, 1413, 1472, 1532

Alkphase-B® (Bone alkaline phosphatase [BAP] EIA)

see also Bone alkaline phosphatase, other methods

<i>biological variation, age</i>	968, 1025, 1465, 1485
<i>comparison between methods</i>	866, 908, 909, 910, 914, 1025, 1056, 1093, 1145, 1432, 1465
<i>genetic influence, receptor gene polymorphisms</i>	1322
<i>method</i>	866, 914, 1025
<i>performance characteristics</i>	866, 914, 1025, 1093, 1099
<i>specificity</i>	914, 968, 1025, 1432, 1465
<i>treatment effects</i>	
bisphosphonates	
alendronate.....	1057, 1163
etidronate.....	1056, 1099, 1240
other.....	1056, 1057, 1099, 1129, 1163, 1240
cancer therapy.....	1397
growth hormone (GH).....	968, 1265
hormone replacement therapy (HRT).....	1129, 1163
parathyroid hormone (PTH).....	1445
thyroid disorder therapy.....	1105
transplantation, renal.....	1093

values in

cancer

breast.....	1145, 1397
multiple myeloma.....	1093, 1171
prostate.....	1476
other.....	983
children.....	866, 968, 1432
cirrhosis.....	1145
diabetes	1412
fracture, traumatic.....	1262
growth disorders.....	968

Alkphase-B Continued

values in continued

men.....	909, 914, 1025, 1145, 1485
mineral metabolism disorders, other.....	914
nonskeletal disorders, other.....	1145
osteoporosis, osteopenia.....	914, 1057, 1163
Paget's disease.....	866, 909, 914, 1056, 1099, 1145, 1163, 1432
parathyroid disorders.....	914, 1145
renal dysfunction or transplant.....	1093, 1145
spinal cord injury.....	897
thyroid disorders.....	1105, 1391
women	
postmenopausal.....	909, 1025, 1099, 1145, 1163, 1466, 1485, 1538, 1565
surgically-induced menopause.....	1163
premenopausal.....	909, 914, 1025, 1099, 1145, 1163, 1485, 1538, 1565

Bone alkaline phosphatase, other methods

biological variation

age.....	206, 262, 266, 267, 273, 274, 374, 480, 776, 960, 1160
circadian (diurnal, nyctohemeral).....	597, 1560
circannual, seasonal.....	1536
day to day.....	529, 1135
diet.....	731
ethnicity, race.....	549, 1566
exercise, bed rest.....	405, 784, 1493, 1567
menstrual cycle.....	862
puberty.....	480, 1177, 1396
<i>genetic influence, receptor gene polymorphisms</i>	999, 1028, 1151, 1503
<i>method</i>	266, 271, 274, 374, 380, 709, 739
<i>specificity</i>	1432
<i>stability</i>	861, 1030

treatment effects

androgens.....	1509, 1572
antiepileptics.....	437
bisphosphonates	
alendronate.....	675, 719
etidronate.....	907, 1056
pamidronate.....	374, 885, 1130
other.....	374, 675, 719, 885, 907, 918, 1056, 1130, 1179, 1323
calcium.....	952, 1008, 1061, 1319
cancer therapy.....	734, 787, 1089, 1176, 1514, 1522, 1525
corticosteroids.....	369, 871, 925, 1185, 1291, 1514, 1519, 1522
DMARDs (antirheumatic therapy)	1531
endocrine disorder therapy, other.....	1509
fluoride.....	1400
insulin-like growth factor I (IGF-I).....	1019, 1043, 1481
gonadotropin-releasing hormone (GnRH) analogs.....	1344
growth hormone (GH).....	540, 661, 724, 819, 870, 979, 1019, 1043, 1155, 1481, 1511, 1513, 1522, 1533
hormone replacement therapy (HRT).....	275, 311, 383, 519, 534, 792, 902, 907, 925, 1042, 1061, 1135, 1154, 1299, 1418
parathyroid disorder therapy.....	1300
parathyroid hormone (PTH).....	1508
SERMs (estrogen analogs).....	1014, 1418, 1431
thyroid disorder therapy.....	62, 378, 662, 727, 1447, 1473
transplantation, renal, cardiac or bone marrow.....	369, 734, 1001, 1039, 1093, 1103, 1350, 1428
vitamin D/metabolites.....	947, 952, 1008, 1087, 1319

values in

cancer

breast.....	134, 598, 814, 917, 1145, 1168, 1346, 1347, 1397
multiple myeloma.....	960
prostate.....	261, 630, 787, 1086, 1089, 1475, 1539
other.....	262, 266, 374, 448, 499, 727, 739, 964, 983, 1091, 1137, 1145, 1152, 1160, 1176, 1525, 1528
children.....	260, 269, 273, 275, 393, 542, 739, 776, 819, 871, 960, 1031, 1177, 1432
infants.....	911, 1384

Bone alkaline phosphatase Continued

values in continued

cirrhosis, other liver disease.....	260, 266, 269, 374, 739, 1145
diabetes.....	594, 627
fracture, traumatic.....	817, 854, 1262, 1355
glucocorticoid excess.....	206, 262, 266, 917, 987
growth disorders.....	206, 262, 542, 870, 1155
men.....	62, 206, 262, 267, 273, 275, 374, 380, 739, 776, 784, 909, 917, 960, 1145, 1160
elderly.....	817, 1008, 1293
mineral metabolism disorders, other.....	269, 601, 739, 1156
nonskeletal disorders, other.....	673, 739, 871, 879, 1087, 1088, 1145, 1178, 1523
osteoarthritis.....	1005
osteoporosis.....	206, 262, 540, 651, 675, 705, 719, 812, 817, 1100, 1113, 1160
Paget's disease.....	206, 262, 266, 269, 374, 380, 558, 739, 789, 858, 859, 885, 909, 917, 960, 1056, 1072, 1130, 1145, 1160, 1432
parathyroid disorders.....	206, 262, 266, 269, 374, 738, 739, 917, 939, 952, 1008, 1091, 1145, 1160
renal dysfunction.....	206, 262, 374, 690, 738, 873, 917, 935, 952, 960, 979, 1001, 1145, 1160, 1385, 1527
rheumatoid arthritis.....	600, 879, 925, 1164, 1531
thyroid disorders.....	62, 206, 262, 378, 727, 739, 917, 11324, 1448, 1473
women.....	206, 262, 266, 267, 273, 275, 380, 550, 739, 776, 960, 1160
elderly.....	651, 774, 785, 817, 917, 1054, 1113, 1293
peri-, postmenopausal.....	38, 62, 374, 549, 675, 705, 727, 812, 909, 1054, 1077, 1145, 1160, 1532, 1566
surgically induced.....	383
pregnancy, lactation.....	599, 739, 805, 938, 1000
premenopausal.....	38, 62, 374, 719, 727, 774, 909, 1054, 1077, 1113, 1145, 1160, 1532, 1566

NovoCalcin®* (Osteocalcin [OC] or Bone Gla Protein [BGP] EIA)

see also Osteocalcin, other methods

<i>animal model studies</i>	900, 1051
<i>comparison between methods</i>	533, 1474
<i>method</i>	533
<i>performance characteristics</i>	533
<i>specificity</i>	533
<i>stability</i>	784, 1474, 1543
<i>treatment effects</i>	
androgens.....	791
bisphosphonates.....	907, 1129, 1240
corticosteroids.....	967, 1291, 1388
DMARDs (antirheumatic therapy).....	1217
hormone replacement therapy (HRT).....	907, 967, 1129
parathyroid hormone (PTH).....	1445
thyroid disorder therapy.....	1473
vitamin D/metabolites.....	1388

values in

cancer.....	1171
men.....	533, 791
osteoporosis.....	533
Paget's disease.....	533
rheumatoid arthritis.....	1217
spinal cord injury.....	897
thyroid disorders.....	1391, 1473, 1504
women, pre- and postmenopausal.....	533, 1466

***NovoCalcin is for research use only in the USA. Not for use in diagnostic procedures.**

Osteocalcin, other methods

biological variation

age.....	110, 131, 206, 227, 230, 233, 234, 236, 245, 262, 480, 550, 650, 666, 775, 934, 1085, 1568
circannual, seasonal.....	30, 110, 1536
circadian (diurnal, nyctohemeral).....	130, 131, 410, 597, 1066, 1560
day to day.....	529, 1019, 1135
diet.....	807
ethnicity, race.....	549, 1186, 1510, 1566

Osteocalcin Continued

<i>biological variation</i> continued	
exercise, bedrest	354, 405, 784, 977, 1548, 1567, 1575
menstrual cycle	862
puberty	480, 1177
<i>genetic influence, receptor gene polymorphisms</i>	898, 999, 1028, 1071, 1151, 1322, 1482, 1503, 1515, 1581
<i>performance characteristics</i>	664, 1576
<i>specificity</i>	1576
<i>stability</i>	543, 786, 880, 944, 1474, 1543
<i>treatment effects</i>	
androgens	1509, 1572
antiepileptics	437, 794, 994
bisphosphonates	
alendronate	326, 408, 719, 971, 1023, 1029, 1083, 1456, 1501, 1537
etidronate	245, 1449
pamidronate	853, 906, 916, 972, 1130
other	918, 1065, 1163, 1179, 1323, 1449
calcitonin	55, 388, 414, 544, 580, 773, 901, 1023, 1094, 1097, 1167, 1526, 1541, 1580
calcium	732, 956, 1008, 1061, 1319, 1329, 1568
cancer therapy	226, 246, 653, 734, 1176, 1296, 1516, 1517, 1525
cirrhosis therapy	551, 563
corticosteroids	55, 409, 438, 527, 587, 628, 668, 669, 670, 761, 782, 846, 855, 871, 925, 990, 1034, 1082, 1162, 1185, 1290, 1518, 1519
endocrine disorder therapy, other	1509
DMARDs (antirheumatic therapy)	579
fluoride	1329, 1400, 1579
gonadotropin-releasing hormone (GnRH) analogs	991
growth hormone (GH)	382, 440, 475, 535, 540, 666, 724, 761, 811, 870, 901, 916, 972, 979, 996, 1019, 1043, 1188, 1265, 1328, 1360, 1481, 1497, 1511, 1533, 1541, 1580
hormone replacement therapy (HRT)	208, 311, 318, 383, 414, 493, 519, 534, 546, 593, 665, 729, 792, 840, 925, 1042, 1061, 1135, 1163, 1166, 1188, 1299, 1477, 1581
dosage adjustment	766
insulin-like growth factor I (IGF-I)	933, 1019, 1043, 1188, 1481
ipriflavone	749, 1526
parathyroid disorder therapy	497, 545, 668, 869
parathyroid hormone (PTH)	388, 735, 924, 974, 991, 1508
SERMs (estrogen analogs)	653, 1014, 1150, 1431
thyroid disorder therapy	60, 62, 243, 378, 584, 662, 751, 939, 978, 1447, 1578
tibolone	1357
transplantation, cardiac, renal, liver or bone marrow	563, 734, 1001, 1064, 1103, 1390, 1422, 1428, 1438, 1491
vitamin D/metabolites	668, 710, 840, 947, 952, 956, 1008
<i>undercarboxylated</i>	453, 676, 937, 975, 1576
<i>values in</i>	
arthritis	628
cancer	
breast	246, 399, 653, 917, 1168
multiple myeloma	772, 1065, 1084
prostate	226, 1086, 1296, 1476
other	245, 254, 262, 499, 653, 917, 997, 1065, 1084, 1086, 1091, 1152, 1168, 1176, 1516, 1517, 1525
children	236, 410, 542, 668, 871, 1031, 1177, 1384, 1568, 1574
infants	934, 985, 1085
cirrhosis, other liver disorders	254, 551, 563, 710
diabetes	594, 668, 931, 1412
fracture, traumatic	701, 854, 921, 1009, 1355
glucocorticoid excess	206, 255, 262, 917, 987
growth disorders	103, 206, 262, 382, 410, 542, 649, 666, 700, 724, 870, 972, 996
men	62, 206, 233, 234, 245, 254, 262, 412, 451, 784, 917
elderly	182, 817, 1293
mineral metabolism disorders, other	92, 668, 1304, 1520
nonskeletal disorders, other	61, 254, 671, 672, 673, 846, 871, 1012, 1088, 1178, 1523
osteoporosis, osteopenia	23, 92, 101, 130, 206, 229, 239, 254, 262, 388, 409, 493, 526, 540, 651, 667, 705, 708, 719, 773, 812, 817, 921, 936, 1009, 1094, 1160, 1163, 1456
fracture	1113, 1576
Paget's disease	206, 231, 245, 254, 255, 262, 409, 414, 558, 708, 789, 917, 1072, 1130, 1160
parathyroid disorders	92, 206, 245, 254, 255, 262, 409, 451, 497, 545, 668, 735, 869, 917, 939, 952, 953,

Osteocalcin Continued

values in continued

parathyroid disorders continued.....	1008, 1064, 1091, 1160, 1535
rheumatoid arthritis.....	522, 523, 579, 650, 670, 808, 925, 1162, 1164, 1413
renal dysfunction.....	206, 227, 245, 255, 262, 409, 589, 664, 690, 708, 779, 873, 917, 935, 952, 953, 954,955, 956, 979, 1001, 1064
spinal cord injury.....	951
thyroid disorders.....	60, 62, 92, 206, 243, 255, 262, 378, 584, 664, 917, 1324, 1448
women.....	182, 206, 229, 233, 234, 245, 254, 262, 451, 550, 927, 1008, 1565
elderly.....	651, 774, 785, 817, 980, 1054, 1113, 1293, 1535, 1576
peri-, postmenopausal.....	23, 38, 62, 101, 163, 250, 414, 493, 549, 580, 650, 665, 705, 726, 775,812, 929, 936, 980, 1054, 1077, 1080, 1159, 1163, 1413, 1532, 1538, 1566
surgically-induced	383, 766, 1036, 1163, 1521
pregnancy, lactation.....	245, 409, 414, 599, 648, 699, 805, 938, 978, 985, 1000, 1021, 1092
premenopausal.....	23, 38, 62, 163, 250, 650, 665, 719, 726, 774, 775, 936, 1054, 1077, 1113,1163, 1413, 1532, 1535, 1538, 1566

Prolagen-C®* (Collagen type I C-terminal Propeptide [CICP] EIA)

see also Collagen propeptide, other methods

<i>biological variation, age, puberty</i>	514, 968
<i>comparison between methods</i>	534
<i>genetic influence, receptor gene polymorphisms</i>	999, 1028, 1151, 1581
<i>method</i>	220
<i>performance characteristics</i>	219
<i>treatment effects</i>	
bisphosphonates.....	907, 918, 1129
calcitonin.....	1580
calcium	1319
corticosteroid.....	1388
growth hormone (GH).....	514, 968, 1019, 1215, 1580
hormone replacement therapy (HRT).....	519, 902, 907, 1042, 1129, 1581
insulin-like growth factor I (IGF-I).....	1019
renal transplantation.....	1039, 1093
vitamin D/metabolites.....	1388

values in

cancer	514, 1093, 1137, 1171
children, infants.....	514, 911, 968
growth disorders.....	514, 968, 1215
osteoporosis.....	1054
Paget's disease.....	858
thyroid disorders.....	1391
transplantation, renal.....	1039, 1093
women, pre- & postmenopausal.....	1054

***Prolagen-C is for research use only in the USA. Not for use in diagnostic procedures.**

Collagen propeptide, other methods

biological variation

age.....	206, 215, 217, 218, 390, 480, 650, 934
circadian (diurnal, nyctohemeral).....	142, 410, 1066
day to day.....	529, 1135
diet.....	807
exercise, bedrest.....	758, 784, 977, 1493, 1548, 1567
puberty.....	390, 480
<i>genetic influence, receptor gene polymorphisms</i>	1026, 1322, 1503

treatment effects

androgens.....	1572
antiepileptics.....	437, 994
bisphosphonates	
alendronate.....	719
etidronate.....	1449
pamidronate.....	906, 916, 972, 1130
other.....	943, 1179, 1449, 1492

Collagen propeptide Continued

treatment effects continued

calcitonin.....	388, 544, 578, 1097
calcium.....	581, 1329
cancer therapy.....	653, 1348, 1517, 1522
corticosteroids.....	209, 215, 527, 587, 761, 816, 855, 1034, 1082, 1162, 1185, 1290, 1519, 1522
fluoride.....	1329, 1400
gonadotropin-releasing hormone (GnRH) analogs.....	390
growth hormone (GH).....	382, 475, 535, 540, 724, 761, 811, 870, 916, 972, 979, 996, 1011, 1019, 1043, 1188, 1328, 1360, 1481, 1497, 1511, 1513, 1522, 1533
hormone replacement therapy (HRT).....	208, 209, 210, 524, 578, 792, 840, 1135, 1166, 1188, 1299, 1418
insulin-like growth factor I (IGF-I).....	933, 1043, 1188, 1481
parathyroid disorder therapy.....	497, 545, 1300
parathyroid hormone (PTH).....	388, 735
renal failure therapy; or transplantation.....	495, 1001
SERMs (estrogen analogs).....	653, 662, 1170
thyroid disorder therapy.....	584, 662, 1170
vitamin D/metabolites.....	207, 581, 840

values in

cancer	
breast.....	725, 1168
multiple myeloma.....	478
prostate.....	943, 1348
other.....	923, 1091, 1152, 1187, 1517
children.....	215, 217, 390, 410, 542, 1011, 1384, 1558
infants.....	934
diabetes.....	1558
fracture, traumatic.....	854, 942
glucocorticoid excess.....	206, 987
growth disorders.....	206, 217, 382, 410, 542, 649, 700, 724, 870, 972, 996, 1011, 1360
men.....	206, 215, 725, 784, 1178
mineral metabolism disorders, other.....	92, 1304
nonskeletal disorders, other.....	218, 581, 672, 681, 718, 806, 1012, 1178, 1523
osteoporosis.....	92, 206, 215, 388, 526, 540, 651, 705, 719, 936, 941, 1009
Paget's disease.....	206, 216, 789, 1130, 1365
parathyroid disorders.....	92, 206, 215, 386, 497, 545, 735, 941, 953, 1091
renal dysfunction.....	206, 495, 779, 935, 953, 954, 955, 979, 1001
rheumatoid arthritis.....	525, 650, 1162, 1164
spinal cord injury.....	951
thyroid disorders.....	92, 206, 386, 584, 941, 1170
women.....	206, 215, 452, 725
elderly.....	651, 758, 980, 1055
postmenopausal.....	210, 524, 578, 650, 705, 936, 980, 1077, 1538
pregnancy, lactation.....	805, 1000, 1021
premenopausal.....	210, 578, 650, 719, 936, 1077, 1538

Bibliography

- Johnston JD, Koneru S, Kuwana T, Rosalki SB. Bone-derived serum enzymes and bone density in perimenopausal caucasian women. *Ann Clin Biochem* 1993;30:191-194.
- Podenphant J, Johansen JS, Thomsen K, Riis BJ, Leth A, Christiansen C. Bone turnover in spinal osteoporosis. *J Bone Miner Res* 1987;2:497-503.
- Dawson-Hughes B, Harris S. Thiazides and seasonal bone change in healthy postmenopausal women. *Bone Miner* 1993;21:41-51.
- Sowers MR, Clark MK, Hollis B, Wallace RB, Jannausch M. Radial bone mineral density in pre- and perimenopausal women: A prospective study of rates and risk factors for loss. *J Bone Miner Res* 1992;7:647-657.
- Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis: A comparison of calcium, calcitriol, and calcitonin. *N Engl J Med* 1993;328:1747-1752.
- Harvey RD, McHardy KC, Reid IW, et al. Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridinium cross-links as specific urinary markers. *J Clin Endocrinol Metab* 1991;72:1189-1194.
- Seibel MJ, Gartenberg F, Silverberg SJ, Ratcliffe A, Robins SP, Bilezikian JP. Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism. *J Clin Endocrinol Metab* 1992;74:481-486.
- Stepán JJ, Límanová Z. Biochemical assessment of bone loss in patients on long-term thyroid hormone treatment. *Bone Miner* 1992;17:377-388.

64. Klein GL, Herndon DN, Rutan TC, et al. Bone disease in burn patients. *J Bone Miner Res* 1993;8:337-345.
71. Schlemmer A, Johansen JS, Pedersen SA, Jorgensen JOL, Hassager C, Christiansen C. The effect of growth hormone (GH) therapy on urinary pyridinoline cross-links in GH-deficient adults. *Clin Endocrinol* 1991;35:471-476.
88. Bettica P, Moro L, Robins SP, et al. Bone resorption markers galactosyl hydroxylysine, pyridinium crosslinks, and hydroxyproline compared. *Clin Chem* 1992;38:2313-2318.
89. Bettica P, Baylink DJ, Moro L. Galactosyl hydroxylysine and deoxypyridinoline: A methodological comparison. *Eur J Clin Chem Clin Biochem* 1993;31:459-465.
92. Charles P, Hasling C, Risteli L, Mosekilde L, Eriksen EF. Assessment of bone formation by biochemical markers in metabolic bone disease: Separation between osteoblastic activity at the cell and tissue level. *Calcif Tissue Int* 1992;51:406-411.
93. Cooper EH, Jones RG. Biochemical markers of bone metastases. *Tumor Marker Update* 1993;5:1-4.
101. Eastell R, Robins SP, Colwell T, Assiri AMA, Riggs BL, Russell RGG. Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. *Osteoporosis Int* 1993;3:255-260.
103. Ezzat S, Melmed S, Endres D, Eyre DR, Singer FR. Biochemical assessment of bone formation and resorption in acromegaly. *J Clin Endocrinol Metab* 1993;76:1452-1457.
110. Parviainen MT, Pirskanen A, Mahonen A, Alhava EM, Mäenpää PH. Use of non-collagen markers in osteoporosis studies. *Calcif Tissue Int* 1991;49 (suppl):S26-S30.
118. Alam C, Thompson PW, James IT. Urinary excretion of deoxypyridinoline as a marker of bone resorption in an animal model of inflammation associated osteoporosis. In: Christiansen C, Overgaard K, eds. *Osteoporosis 1990*. Copenhagen: Osteopress ApS, 1990:521-522.
119. Beardsworth LJ, Eyre DR, Dickson IR. Changes with age in the urinary excretion of lysyl and hydroxylslypyridinoline, two new markers of bone collagen turnover. *J Bone Miner Res* 1990;5:671-676.
120. Black D, Duncan A, Robins SP. Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reverse-phase high-performance liquid chromatography. *Anal Biochem* 1988;169:197-203.
121. Black D, Farquharson C, Robins SP. Excretion of pyridinium cross-links of collagen in ovariectomized rats as urinary markers for increased bone resorption. *Calcif Tissue Int* 1989;44:343-347.
122. Black D, Marabani M, Aturrock RD, Robins SP. Urinary excretion of the hydroxypyridinium crosslinks of collagen in patients with rheumatoid arthritis. *Ann Rheum Dis* 1989;48:
124. Body JJ, Delmas PD. Urinary pyridinium crosslinks as markers of bone resorption in tumor-associated hypercalcemia. *J Clin Endocrinol Metab* 1992;74:471-475.
126. Coleman R, Houston S, James I, et al. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease. *Br J Cancer* 1993;65:766-768.
128. Delmas PD, Schlemmer A, Gineyts E, Riis B, Christiansen C. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. *J Bone Miner Res* 1991;6:639-644.
129. Eastell R, Hampton L, Colwell A, et al. Urinary collagen crosslinks are highly correlated with radioisotopic measurements of bone resorption. In: Christiansen C, Overgaard K, eds. *Osteoporosis 1990*. Copenhagen: Osteopress ApS, 1990:469-470.
130. Eastell R, Calvo MS, Burritt MF, Offord KP, Russell GG, Riggs BL. Abnormalities in circadian patterns of bone resorption and renal calcium conservation in type I osteoporosis. *J Clin Endocrinol Metab* 1992;74:487-494.
131. Eastell R, Simmons PS, Colwell A, et al. Nyctohemeral changes in bone turnover assessed by serum bone gla-protein concentration and urinary deoxypyridinoline excretion: effect of growth and ageing. *Clin Sci* 1992;83:375-382.
132. Eyre D. Collagen cross-linking amino acids. *Methods in Enzymology* 1987;115-139.
133. Eyre DR, Koob TJ, VanNess KP. Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography. *Anal Biochem* 1984;137:380-388.
134. Frenay M, Namer M, Boubil JL, et al. Value of urinary hydroxyproline and bone isoenzyme of alkaline phosphate in the early detection and follow-up of bone metastasis in breast cancer patients. *Bull Cancer* 1988;75:533-539.
136. Fujimoto D, Moriguchi T. Pyridinoline, a non-reducible crosslink of collagen. *J Biochem* 1978;83:863-867.
137. Fujimoto D, Suzuki M, Uchiyama A, Miyamoto S, Inoue T. Analysis of pyridinoline, a cross-linking compound of collagen fibers in human urine. *J Biochem* 1983;94:1133-1136.
138. Gough AK, Peel NF, Eastell R, Holder RL, Lilley J, Emery P. Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. *Ann Rheum Dis* 1994;53:14-17.
141. Hassager C, Colwell A, Assiri AMA, Eastell R, Russell RGG, Christiansen C. Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium crosslinks: A longitudinal and cross-sectional study. *Clin Endocrinol* 1992;37:45-50.
142. Hassager C, Risteli J, Risteli L, Jensen SB, Christiansen C. Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women. *J Bone Miner Res* 1992;7:1307-1311.
147. McLaren AM, Hordon LD, Bird HA, Robins SP. Urinary excretion of pyridinium crosslinks of collagen in patients with osteoporosis and the effects of fracture. *Ann Rheum Dis* 1992;51:648-651.
149. Paterson CR, Robins SP, Horobin JM, Preece PE, Cuschieri A. Pyridinium crosslinks as markers of bone resorption in patients with breast cancer. *Br J Cancer* 1991;64:884-886.
150. Preedy VR, Sherwood RA, Akpoguma CIO, Black D. The urinary excretion of the collagen degradation markers pyridinoline and deoxypyridinoline in an experimental rat model of alcoholic bone disease. *Alcohol & Alcoholism* 1991;26:191-198.
151. Ricard-Blum S, Ville G, Grimaud J. Hydroxypyridinium collagen crosslinks in human liver fibrosis: Study of alveolar echinococcosis. *Hepatology* 1992;15:599-602.

154. Robins SP, Black D, Paterson CR, Reid DM, Duncan A, Seibel MJ. Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases. *Eur J Clin Invest* 1991;21:310-315.
157. Robins SP, Stewart P, Astbury C, Bird HA. Measurement of the cross linking compound, pyridinoline, in urine as an index of collagen degradation in joint disease. *Ann Rheum Dis* 1986;45:969-973.
158. Schlemmer A, Hassager C, Jensen SB, Christiansen C. Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. *J Clin Endocrinol Metab* 1992;74:476-480.
159. Seibel MJ, Cosman F, Shen V, et al. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. *J Bone Miner Res* 1993;8:881-889.
160. Seibel MJ, Duncan A, Robins SP. Urinary hydroxypyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases. *J Rheumatol* 1989;16:964-970.
161. Seibel MJ, Robins SP, Bilezikian JP. Urinary pyridinium crosslinks of collagen. Specific markers of bone resorption in metabolic bone disease. *Trends Endocrinol Metab* 1992;3:263-270.
163. Thompson PW, Spector TD, Edwards AC, James IT. Urinary deoxypyridinoline and serum osteocalcin as measures of bone metabolism in early postmenopausal women: distribution and comparison with other measures. In: Christiansen C, Overgaard K, eds. Osteoporosis 1990. Copenhagen: Osteopress ApS, 1990:493-495.
164. Uebelhart D, Gineyts E, Chapuy MC, Delmas PD. Urinary excretion of pyridinium crosslinks: A new marker of bone resorption in metabolic bone disease. *Bone Miner* 1990;8:87-96.
165. Uebelhart D, Schlemmer A, Johansen J, Gineyts E, Christiansen C, Delmas PD. Effect of menopause and hormone therapy on the urinary excretion of pyridinium cross-links. *J Clin Endocrinol Metab* 1991;72:367-373.
186. Gilson G, Bernardo Noriega Y, Schmidt P, Ries F, Dicato M, Humbel RL. Immunoassay for urinary pyridinium crosslinks: Markers of bone resorption in cancer patients. *The European Ligand Assay Association, Florence, Italy, April 11-13 1994*; (abst)
192. Kung VT, Gomez B, Lundgard R, Seyedin S, Clark B, Riggs BL. An immunoassay for the measurement of free pyridinoline in serum: A marker of bone resorption. *J Bone Miner Res* 1993;8(Suppl.1):S151. (abst)
197. Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ. Direct enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. *J Bone Miner Res* 1994;9:1643-1649.
198. Robins SP. An enzyme-linked immunoassay for the collagen cross-link pyridinoline. *Biochem J* 1982;207:617-620.
199. Seibel MJ, Schmidt-Gayk H, Stracke H, Burckhardt P. Biochemical markers of bone metabolism are affected by non-skeletal diseases involving collagen turnover. *J Bone Miner Res* 1993;8(Suppl.1):S287. (abst)
203. Shapiro JR, Rachis R, Bellatoni M, Harman SM, Blackman MR. The effect of IGF-1 on skeletal turnover in postmenopausal women. *J Bone Miner Res* 1993;8(Suppl.1):S327. (abst)
206. Ebeling PR, Peterson JM, Riggs BL. Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. *J Bone Miner Res* 1992;7:1243-1250.
207. Gram J, Bollersley J, Nielsen HK, Junker P. Increased serum concentrations of type I procollagen C-terminal propeptide and osteocalcin during a short course of calcitriol administration to adult male volunteers. *Acta Endocrinol* 1991;125:609-613.
208. Hasling C, Eriksen EF, Melkko J, et al. Effects of a combined estrogen-gestagen regimen on serum levels of the carboxy-terminal propeptide of human type I procollagen in osteoporosis. *J Bone Miner Res* 1991;6:1295-1300.
209. Hassager C, Jensen LT, Johansen JS, et al. The carboxyterminal propeptide of type I procollagen in serum as a marker of bone formation: The effect of nandrolone decanoate and female sex hormones. *Metabolism* 1991;40:205-208.
210. Hassager C, Fabbri-Mabelli G, Christiansen C. The effect of the menopause and hormone replacement therapy on serum carboxyterminal propeptide of type I collagen. *Osteoporosis Int* 1993;3:50-52.
213. Parfitt AM, Simon LS, Villaneuva AR, Krane SM. Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone: Correlation with iliac bone formation rates and comparison with total alkaline phosphatase. *J Bone Miner Res* 1987;2:427-436.
215. Saggese G, Bertelloni S, Baroncelli GI, Di Nero G. Serum levels of carboxyterminal propeptide of type I procollagen in healthy children from 1st year of life to adulthood and in metabolic bone diseases. *Eur J Pediatr* 1992;151:764-768.
216. Simon LS, Krane SM, Wortman PD, Krane IM, Kovitz KL. Serum levels of type I and III procollagen fragments in Paget's disease of bone. *J Clin Endocrinol Metab* 1984;55:110-120.
217. Trivedi P, Risteli J, Risteli L, Hindmarsh PC, Brook CGD, Mowat AP. Serum concentrations of type I and III procollagen propeptides as biochemical markers of growth velocity in healthy infants and children and in children with growth disorders. *Pediatr Res* 1991;30:276-280.
218. Vainionpää L, Risteli L, Lanning M, Risteli J. Carboxyterminal propeptide of type I procollagen in cerebrospinal fluid in childhood and in children with leukemia undergoing intrathecal treatment. *Clin Chem* 1991;37:1365-1369.
224. Hanson DA, Weis MAE, Bollen AM, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. *J Bone Miner Res* 1992;7:1251-1258.
226. Arai Y, Takeuchi H, Oishi K, Yoshida O. Osteocalcin: Is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer? *Prostate* 1992;20:169-177.
227. Catherwood BD, Marcus R, Madvig P, Cheung AK. Determinants of bone gamma-carboxyglutamic acid-containing protein in plasma of healthy aging subjects. *Bone* 1985;6:9-13.
229. Delmas PD, Stenner D, Wahner HW, Mann KG, Riggs BL. Assessment of bone turnover in postmenopausal osteoporosis by measurement of serum bone gla-protein. *J Lab Clin Med* 1983;102:470-476.
230. Delmas PD, Stenner D, Wahner HW, Mann KG, Riggs BL. Increase on serum bone gamma carboxyglutamic acid protein with aging in women. *J Clin Invest* 1983;71:1316-1321.
231. Delmas PD, Demiaux B, Malaval L, Chapuy MC, Meunier PJ. Serum bone GLA-protein is not a sensitive marker of bone turnover in Paget's disease of bone. *Calcif Tissue Int* 1986;38:60-61.

232. Delmas PD, Christiansen C, Mann KG, Price PA. Bone gla protein (osteocalcin assay standardization report). *J Bone Miner Res* 1990;5:5-11.
233. Epstein S, Poser J, McClintock R, Johnston CC, Bryce G, Hui S. Differences in serum bone GLA protein with age and sex. *Lancet* 1984;307-310.
234. Galli M, Caniggia M. Osteocalcin in normal adult humans of different sex and age. *Horm Metabol Res* 1984;17:165-166.
236. Gundberg CM, Lian JB, Gallop PM. Measurements of gamma-carboxyglutamate and circulating osteocalcin in normal children and adults. *Clin Chim Acta* 1983;128:1-8.
239. Ismail F, Epstein S, Pacifici R, Droke D, Thomas SB, Avioli LV. Serum bone gla protein (BGP) and other markers of bone mineral metabolism in postmenopausal osteoporosis. *Calcif Tissue Int* 1986;39:230-233.
243. Kojima N, Sakata S, Nakamura S. Serum concentrations of osteocalcin in patients with hyperthyroidism, hypothyroidism, and subacute thyroiditis. *J Endocrinol Invest* 1992;15:491-496.
245. Melick RA, Farrugia W, Qualch KG. Plasma osteocalcin in man. *Aus NZ J Med* 1985;15:410-416.
246. Neri B, Cecchetti M, Pacini P, Bartalucci S, Gemelli MT, Giorgi F. Osteocalcin as a biological marker in the therapeutic management of breast cancer bone metastases. *Cancer Invest* 1989;7:551-555.
250. Pansini F, Bonaccorsi G, Calisesi M, et al. Evaluation of bone metabolic markers as indicators of osteopenia in climacteric women. *Gynecol Obstet Invest* 1992;33:231-235.
254. Price PA, Parthemore JG, Deftos LJ, Nishimoto SK. New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone gla protein in the plasma of normal subjects and patients with bone disease. *J Clin Invest* 1980;66:878-883.
255. Riggs BL, Mann KG. Assessment of metabolic bone diseases by measurement of serum bone gla-protein. In: Sen A, Thornhill T, eds. Development of diseases of cartilage and bone matrix. New York: Alan R Liss, 1987:177-186.
258. Tracy RP, Andrianorivo A, Riggs BL, Mann KG. Comparison of monoclonal and polyclonal antibody-based immunoassays for osteocalcin: A study of sources of variation in assay results. *J Bone Miner Res* 1990;5:451-461.
260. Crofton PM. Wheat-germ lectin affinity electrophoresis for alkaline phosphatase isoforms in children: Age-dependent reference ranges and changes in liver and bone disease. *Clin Chem* 1992;38:663-670.
261. Desoize B, Amico S, Larbre H, Coninx P, Jardillier JC. Phosphatase isoenzymes as bone metastasis markers in prostatic carcinoma. *Clin Biochem* 1991;24:443-446.
262. Duda RJ, O'Brien JF, Katzmann JA, Peterson JM, Mann KG, Riggs BL. Concurrent assays of circulating bone gla protein and bone alkaline phosphatase: Effects of sex, age, and metabolic bone disease. *J Clin Endocrinol Metab* 1988;66:951-957.
266. Gonchoroff DG, Branum EL, Cedel SL, Riggs BL, O'Brien JF. Clinical evaluation of high performance affinity chromatography for the separation of bone and liver alkaline phosphatase isoenzymes. *Clin Chim Acta* 1991;199:43-50.
267. Kuwana T, Sugita O, Yakata M. Reference limits of bone and liver alkaline phosphatase isoenzymes in the serum of healthy subjects according to age and sex as determined by wheat germ lectin affinity electrophoresis. *Clin Chim Acta* 1988;173:273-280.
269. Miura M, Matsuzaki H, Bailyles EM, et al. Differences between human liver and bone type alkaline phosphatases. *Clin Chim Acta* 1989;180:177-188.
271. Rosalki SB, Ying Foo A. Two new methods for separating and quantifying bone and liver alkaline phosphatase isoenzymes in plasma. *Clin Chem* 1984;30:1182-1186.
273. Schiele F, Henny J, Hitz J, Petitclerc C, Gueguen R, Siest G. Total bone and liver alkaline phosphatases in plasma: biological variations and reference limits. *Clin Chem* 1983;29:634-641.
274. Seabrook RN, Baiyles EM, Price CP, Siddle K, Luzio JP. The distinction of bone and liver isoenzymes of alkaline phosphatase in serum using a monoclonal antibody. *Clin Chim Acta* 1988;172:261-266.
275. Sorenson S. Wheat-germ lectin agglutination method for measuring bone and liver isoenzymes of alkaline phosphatase assessed in postmenopausal osteoporosis. *Clin Chem* 1988;34:1636-1640.
311. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. *Ann Intern Med* 1992;117:1-9.
318. Trémollières F, Pouilles J-M, Ribot C. Effect of long-term administration of progestogen on post-menopausal bone loss: Result of a two-year, controlled randomized study. *Clin Endocrinol* 1993;38:627-631.
326. Harris ST, Gertz BJ, Genant HK, et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. *J Clin Endocrinol Metab* 1993;76:1399-1406.
332. Rosen HN, Moses AC, Gundberg C, et al. Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humans. *J Clin Endocrinol Metab* 1993;77:664-669.
354. Hetland ML, Haarbo J, Christiansen C. Low bone mass and high bone turnover in male long distance runners. *J Clin Endocrinol Metab* 1993;77:770-775.
369. van Straalen JP, Sanders E, Prummel MF, Sanders GTB. Bone-alkaline phosphatase as indicator of bone formation. *Clin Chim Acta* 1991;201:27-34.
370. Abbiati G, Bartucci F, Longoni A, et al. Monitoring of free and total urinary pyridinoline and deoxypyridinoline in healthy volunteers: Sample relationships between 24-h and fasting early morning urine concentrations. *Bone Miner* 1993;21:9-19.
372. Delmas PD, Gineyts E, Bertholin A, Garnero P, Marchand F. Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease. *J Bone Miner Res* 1993;8:643-648.
373. Hamdy NAT, Papapoulos SE, Colwell A, Eastell R, Russell RGG. Urinary collagen crosslink excretion: A better index of bone resorption than hydroxyproline in Paget's disease of bone? *Bone Miner* 1993;22:1-8.
374. Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. *J Clin Endocrinol Metab* 1993;77:1046-1053.
377. Calabresi E, Lasagni L, Franceschelli F, Bartolini L, Serio M, Brandi ML. Use of an internal standard to measure pyridinoline and deoxypyridinoline in urine [letter]. *Clin Chem* 1994;40:336-337.
378. Garnero P, Vassy V, Bertholin A, Riou JP, Delmas PD. Markers of bone turnover in hyperthyroidism and the effects of treatment. *J Clin Endocrinol Metab* 1994;78:955-959.
380. Panigrahi K, Delmas PD, Singer F, et al. Characteristics of a two-site immunoradiometric assay for human skeletal alkaline phosphatase in serum. *Clin Chem* 1994;40:822-828.

381. Ricard-Blum S, Ville G, Grimaud J-A. Pyridinoline, a mature collagen cross-link, in fibrotic livers from *Schistosoma mansoni*-infected mice. *Am J Trop Med Hyg* 1992;47:816-820.
382. Saggese G, Baroncelli GI, Bertelloni S, Cinquanta L, Di Nero G. Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency. *J Pediatr* 1993;122:37-45.
383. Field CS, Ory SJ, Wahner HW, Herrmann RR, Judd HL, Riggs BL. Preventive effects of transdermal 17 β -estradiol on osteoporotic changes after surgical menopause: A two-year placebo-controlled trial. *Am J Obstet Gynecol* 1993;168:114-121.
386. Eriksen EF, Charles P, Melsen F, Mosekilde L, Risteli L, Risteli J. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. *J Bone Miner Res* 1993;8:127-132.
388. Hodsman AB, Fraher LJ, Ostbye T, Adachi JD, Steer BM. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. *J Clin Invest* 1993;91:1138-1148.
390. Hertel NT, Stoltenberg M, Juul A, et al. Serum concentrations of type I and III procollagen propeptides in healthy children and girls with central precocious puberty during treatment with gonadotropin-releasing hormone analog and cyproterone acetate. *J Clin Endocrinol Metab* 1993;76:924-927.
391. Lipton A, Demers L, Daniloff Y, et al. Increased urinary excretion of pyridinium cross-links in cancer patients. *Clin Chem* 1993;39:614-618.
393. Rosalki SB, Foo AY, Burlina A, et al. Multicenter evaluation of Iso-ALP test kit for measurement of bone alkaline phosphatase activity in serum and plasma. *Clin Chem* 1993;39:648-652.
394. Seyedin SM, Kung VT, Daniloff YN, et al. Immunoassay for urinary pyridinoline: The new marker of bone resorption. *J Bone Miner Res* 1993;8:635-641.
399. Kamy C, Egsmose C, Söletormos G, Dombernowsky P. The diagnostic and prognostic value of serum bone Gla protein (osteocalcin) in patients with recurrent breast cancer. *Scand J Clin Lab Invest* 1993;53:439-446.
404. Ricard-Blum S, Esterre P, Grimaud J-A. Collagen cross-linking by pyridinoline occurs in non-reversible skin fibrosis. *Cell Mol Biol* 1993;39:723-727.
405. Lueken SA, Arnaud SB, Taylor AK, Baylink DJ. Changes in markers of bone formation and resorption in a bed rest model of weightlessness. *J Bone Miner Res* 1993;8:1433-1438.
407. Hashimoto K, Nozaki M, Yokoyama M, Sano M, Nakano H. Urinary excretion of pyridinium crosslinks of collagen in oophorectomized women as markers for bone resorption. *Maturitas* 1994;18:135-142.
408. Gertz BJ, Shao P, Hanson DA, et al. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. *J Bone Miner Res* 1994;9:135-142.
409. Masters PW, Jones RG, Purves DA, Cooper EH, Cooney JM. Commercial assays for serum osteocalcin give clinically discordant results. *Clin Chem* 1994;40:358-363.
410. Saggese G, Baroncelli GI, Bertelloni S, Cinquanta L, DiNero G. Twenty-four-hour osteocalcin, carboxyterminal propeptide of type I procollagen, and aminoterminal propeptide of type III procollagen rhythms in normal and growth-retarded children. *Pediatr Res* 1994;35:409-415.
411. Kimble RB, Vannice JL, Bloedow DC, et al. Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. *J Clin Invest* 1994;93:1959-1967.
412. Johansson AG, Forslund A, Hambræus L, Blum WF, Ljunghall S. Growth hormone-dependent insulin-like growth factor binding protein is a major determinant of bone mineral density in healthy men. *J Bone Miner Res* 1994;9:915-921.
414. Parthemore JG, Burton DW, Defetos LJ. Associations and dissociations between serum bone Gla protein and alkaline phosphatase in skeletal metabolism. *J Orthop Res* 1993;11:671-676.
432. Kotowicz MA, Jones JD, O'Fallon WM, Eriksen E, Eastell R, Riggs BL. Total 24-hour pyridinium crosslink excretion correlates with cancellous bone resorption rate. *Bone Miner* 1992;17(Suppl.):139. (abst)
436. Sakura S, Fujimoto D, Sakamoto K, Mizuno A, Katsutoshi M. Photolysis of pyridinoline, a cross-linking amino acid of collagen, by ultraviolet light. *Can J Biochem* 1982;60:525-529.
437. Välimäki MJ, Tiihonen M, Laitinen K, et al. Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. *J Bone Miner Res* 1994;9:631-637.
438. Reid IR, Chapman GE, Fraser TRC, et al. Low serum osteocalcin levels in glucocorticoid-treated asthmatics. *J Clin Endocrinol Metab* 1986;62:379-383.
440. Clemmesen B, Overgaard K, Riis B, Christiansen C. Human growth hormone and growth hormone releasing hormone: A double-masked, placebo-controlled study of their effects on bone metabolism in elderly women. *Osteoporosis Int* 1994;3:330-336.
445. Fincato G, Bartucci F, Rigoldi M, et al. Urinary excretion of pyridinoline and deoxypyridinoline: Circadian rhythm in healthy premenopausal women. *J Interdiscipl Cycle Res* 1993;24:72-78.
446. Chesnut CH, Harris ST. Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women. *Osteoporosis Int* 1993;Suppl.:S17-S19.
448. Van Hoof VO, Van Oosterom AT, Lepoutre LG, De Broe ME. Alkaline phosphatase isoenzyme patterns in malignant disease. *Clin Chem* 1992;38:2546-2551.
452. Pedersen BJ, Bonde M. Purification of human procollagen type I carboxyl-terminal propeptide cleaved as in vivo from procollagen and used to calibrate a radioimmunoassay of the propeptide. *Clin Chem* 1994;40:811-816.
453. Szulc P, Chapuy M-C, Meunier PJ, Delmas PD. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. *J Clin Invest* 1993;91:1769-1774.
457. Mole PA, Walkinshaw MH, Robins SP, Paterson CR. Can urinary pyridinium crosslinks and urinary oestrogens predict bone mass and rate of bone loss after the menopause? *Eur J Clin Invest* 1992;22:767-771.
458. Robins SP, Duncan A, Riggs BL. Direct measurement of free hydroxy-pyridinium crosslinks of collagen in urine as new markers of bone resorption in osteoporosis. In: Christiansen C, Overgaard K, eds. *Osteoporosis 1990*. Copenhagen: Osteopress ApS, 1992:465-468.
459. Robins SP, Duncan A, McLaren AM. Structural specificity of an ELISA for the collagen crosslink, pyridinoline: implications for the measurement of free pyridinium crosslinks as indices of resorption in metabolic bone diseases. *J Bone Miner Res* 1991;6(Suppl.1):S244. (abst)
464. Ohishi T, Takahashi M, Kushida K, Horiuchi K, Ishigaki S, Inoue T. Quantitative analyses of urinary pyridinoline and deoxypyridinoline excretion in patients with hyperthyroidism. *Endocr Res* 1992;18:281-290.
466. Reginster JY, Christiansen C, Dequinze B, et al. Effect of transdermal 17 β -estradiol and oral conjugated equine estrogens on biochemical parameters of bone resorption in natural menopause. *Calcif Tissue Int* 1993;53:13-16.
468. Ohishi T, Takahashi M, Kawana K, et al. Age-related changes of urinary pyridinoline and deoxypyridinoline in Japanese subjects. *Clin Invest Med* 1993;16:319-325.
472. Ohishi T, Kushida K, Takahashi M, et al. Urinary bone resorption markers in patients with metabolic bone disorders. *Bone* 1994;15:15-20.
474. Miyamoto KK, McSherry SA, Robins SP, Besterman JM, Mohler JL. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma. *J Urol* 1994;151:909-913.
475. Beshyah SA, Thomas E, Kyd P, Sharp P, Fairney A, Johnston DG. The effect of growth hormone replacement therapy in hypopituitary adults on calcium and bone metabolism. *Clin Endocrinol (Oxf)* 1994;40:383-391.
477. Nishimura Y, Fukuoka H, Kiriyama M, et al. Bone turnover and calcium metabolism during 20 days bed rest in young healthy males and females. *Acta Physiol Scand* 1994;150 Suppl. 616:27-35.

478. Abildgaard N, Nielsen JL, Heickendorff L. Connective tissue components in serum in multiple myeloma: Analyses of propeptides of type I and type III procollagens, type I collagen telopeptide, and hyaluronan. *Am J Hematol* 1994;46:173-178.
480. Blumsohn A, Hannon RA, Wrate R, et al. Biochemical markers of bone turnover in girls during puberty. *Clin Endocrinol (Oxf)* 1994;40:663-670.
481. Rauch F, Schönau E, Woitge H, Remer T, Seibel M. Urinary excretion of hydroxy-pyridinium cross-links of collagen reflects skeletal growth velocity in normal children. *Exp Clin Endocrinol* 1994;102:94-97.
484. Stone PJ, Lucey EC, Snider GL, Franzblau C. Effect of diet on urinary excretion of desmosine and hydroxylysyl pyridinoline. *Am J Respir Crit Care Med* 1994;149:174-177.
487. Eyre DR, Dickson IR, Van Ness K. Collagen cross-linking in human bone and articular cartilage. Age-related changes in the content of mature hydroxypyridinium residues. *Biochem J* 1988;252:495-500.
490. Pratt DA, Daniloff Y, Duncan A, Robins SP. Automated analysis of the pyridinium crosslinks of collagen in tissue and urine using solid-phase extraction and reversed-phase high-performance liquid chromatography. *Anal Biochem* 1992;207:168-175.
492. Delmas PD, Donnez J, Chapuy MC, Smets M, Meunier PJ. Short-term effects of transdermal 17 β -oestradiol (Estraderm TTS®) on bone metabolism in oophorectomized women: a placebo-controlled study. In: Christiansen C, Overgaard K, eds. Osteoporosis 1990. Copenhagen: Osteopress ApS, 1990:1985-1990.
493. Eastell R, Colwell A, Assiri AMA, Lufkin EG, Russell RGG, Riggs BL. Prediction of response to estrogen therapy using urine deoxypyridinoline. *J Bone Miner Res* 1990;5:S275. (abst)
494. Colwell A, Russell RGG, Eastell R. Factors affecting the assay of urinary 3-hydroxypyridinium crosslinks of collagen as markers of bone resorption. *Eur J Clin Invest* 1993;23:341-349.
495. Coen G, Ballanti P, Mazzaferro S, Pasquali M, Bonucci E. Procollagen type I C-terminal extension peptide, PTH and 1,25(OH) $_2$ D $_3$ in chronic renal failure. *Bone* 1993;14:415-420.
496. Borisova NV, Pokrovskaya AY, Zakharova EY, Krasnopol'skaya KD. Analysis of collagen hydroxypyridinium crosslinks in samples of tissues and urine of patients with inherited connective tissue disorders. *Connect Tissue Res* 1994;30:177-190.
497. Coen G, Mazzaferro S, De Antoni E, et al. Procollagen type I C-terminal extension peptide serum levels following parathyroidectomy in hyperparathyroid patients. *Am J Nephrol* 1994;14:106-112.
498. Rosalki SB. Bone-origin alkaline phosphatase in plasma by wheat-germ lectin methods in bone disease. *Clin Chim Acta* 1994;226:143-150.
499. Burlina A, Rubin D, Secchiero S, Sciacovelli L, Zaninotto M, Plebani M. Monitoring skeletal cancer metastases with the bone isoenzyme of tissue unspecific alkaline phosphatase. *Clin Chim Acta* 1994;226:151-158.
509. Robins SP, Hamilton N, Nicol P, Boschitsch E, Endler T, Seibel MJ. Bone resorption rates in pre- peri- and postmenopausal women determined by direct immunoassay of deoxypyridinoline. *J Bone Miner Res* 1994;9(Suppl.1):S278. (abst)
514. Winterbottom N, Freeman K, To W-L, Leitzel K, Gargosky SE, Lipton A. Variations in serum levels of the C-terminal propeptide of type I collagen in growth disorders and cancer metastasis. *J Bone Miner Res* 1994;9(Suppl.1):S349. (abst)
519. Prestwood KM, DeSouza MJ, Nulsen JC, Fall PM, Raisz LG. Type I procollagen peptide correlates with bone mass response to hormone replacement therapy. *J Bone Miner Res* 1994;9(Suppl.1):S392. (abst)
527. Oikarinen A, Väänänen K, Risteli L, Risteli J. Systemic glucocorticosteroid decreases serum carboxyterminal propeptide of type I procollagen (PICP) in dermatological patients. In: Christiansen C, Overgaard K, eds. Osteoporosis 1990. Copenhagen: Osteopress ApS, 1990:1644-1645.
529. Blumsohn A, Hannon RA, Al-Dehaimi AW, Eastell R. Short-term intraindividual variability of markers of bone turnover in healthy adults. *J Bone Miner Res* 1994;9(Suppl.1):S153. (abst)
533. Gomez B, Bally CA, Jenkins DK, Kelm RJ, Jr., Seyedin S. An enzyme immunoassay for intact, newly synthesized osteocalcin: A marker of bone formation. *International Conference on Progress in Bone and Mineral Research, Vienna, Austria, October 14-16 1994*; (abst)
534. Prestwood KM, Pilbeam CC, Burleson JA, et al. The short term effects of conjugated estrogen on bone turnover in older women. *J Clin Endocrinol Metab* 1994;79:366-371.
535. Holloway L, Butterfield G, Hintz RL, Gesundheit N, Marcus R. Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women. *J Clin Endocrinol Metab* 1994;79:470-479.
540. Kassem M, Brixen K, Blum WF, Mosekilde L, Eriksen EF. Normal osteoclastic and osteoblastic responses to exogenous growth hormone in patients with postmenopausal spinal osteoporosis. *J Bone Miner Res* 1994;9:1365-1370.
542. Sartorio A, Conti A, Monzani M. New markers of bone and collagen turnover in children and adults with growth hormone deficiency. *Postgrad Med J* 1993;69:846-850.
543. Banfi G, Daverio R. In vitro stability of osteocalcin. *Clin Chem* 1994;40:833-834.
544. Thamsborg G, Skousgaard SG, Daugaard H, Schifter S, Kollerup G, Sorensen OH. Acute effects of nasal salmon calcitonin on calcium and bone metabolism. *Calcif Tissue Int* 1993;53:232-236.
545. Minisola S, Romagnoli E, Scarnecchia L, et al. Serum carboxy-terminal propeptide of human type I procollagen in patients with primary hyperparathyroidism: Studies in basal conditions and after parathyroid surgery. *Eur J Endocrinol* 1994;130:587-591.
548. Egger CD, Mühlbauer RC, Felix R, Delmas PD, Marks SC, Fleisch H. Evaluation of urinary pyridinium crosslink excretion as a marker of bone resorption in the rat. *J Bone Miner Res* 1994;9:1211-1219.
549. Kleerekoper M, Nelson DA, Peterson EL, et al. Reference data for bone mass, calciotropic hormones, and biochemical markers of bone remodeling in older (55-75) postmenopausal white and black women. *J Bone Miner Res* 1994;9:1267-1276.
550. McKane WR, Khosla S, Peterson JM, Egan K, Riggs BL. Circulating levels of cytokines that modulate bone resorption: Effects of age and menopause in women. *J Bone Miner Res* 1994;9:1313-1318.
551. Guañabens N, Parés A, Navasa M, et al. Cyclosporin A increases the biochemical markers of bone remodeling in primary biliary cirrhosis. *J Hepatol* 1994;21:24-28.
553. Seibel MJ, Woitge H, Scheidt-Nave C, et al. Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: Results of a pilot study. *J Bone Miner Res* 1994;9:1433-1440.
554. Farley JR, Hall SL, Ilacas D, et al. Quantification of skeletal alkaline phosphatase in osteoporotic serum by wheat germ agglutinin precipitation, heat inactivation, and a two-site immunoradiometric assay. *Clin Chem* 1994;40:1749-1756.
555. Vanderschueren D, Jans I, Van Herck E, Moermans K, Verhaeghe J, Bouillon R. Time-related increase of biochemical markers of bone turnover in androgen-deficient male rats. *Bone Miner* 1994;26:123-131.
556. Tordjman C, Lhumeau A, Pastoureau P, et al. Evaluation and comparison of urinary pyridinium crosslinks in two rat models of bone loss—ovariectomy and adjuvant polyarthritis—using a new automated HPLC method. *Bone Miner* 1994;26:155-167.
557. Abbiati G, Rigoldi M, Frignani S, Colombo L, Mussini E. Determination of pyridinium crosslinks in plasma and serum by high-performance liquid chromatography. *J Chromatogr B Biomed Appl* 1994;656:303-310.
558. Deftos LJ, Wolfert RL, Hill CS. Bone alkaline phosphatase in Paget's disease. *Horm Metab Res* 1991;11:515-576.

563. Watson RGP, Coulton L, Kanis JA, et al. Circulating osteocalcin in primary biliary cirrhosis following liver transplantation and during treatment with ciclosporin. *J Hepatol* 1990;11:354-358.
567. Robins SP. Cross-linking of collagen: Isolation, structural characteristics, and glycosylation of pyridinoline. *Biochem J* 1983;215:167-173.
578. Sgherzi MR, Fabbri G, Bonati M, et al. Episodic changes of serum procollagen type I carboxy-terminal propeptide levels in fertile and postmenopausal women. *Gynecol Obstet Invest* 1994;38:60-64.
579. Franck H, Ittel TH, Tasch O, Herborn G, Rau R. Osteocalcin in patients with rheumatoid arthritis. A one-year followup study. *J Rheumatol* 1994;21:1256-1259.
580. Overgaard K. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: A dose-response study. *Calcif Tissue Int* 1994;55:82-86.
581. Li F, Iqbal J, Wassif W, Kaddam I, Moniz C. Carboxyterminal propeptide of type I procollagen in osteomalacia. *Calcif Tissue Int* 1994;55:90-93.
584. Legovini P, De Menis E, Da Rin G, et al. Increased serum levels of carboxyterminal propeptide of type I collagen (PICP) in hyperthyroidism. *Horm Metab Res* 1994;26:334-337.
587. Kerstjens HAM, Postma DS, Van Doormaal JJ, et al. Effects of short term and long term treatment with inhaled corticosteroids on bone metabolism in patients with airways obstruction. *Thorax* 1994;49:652-656.
589. Joffe P, Heaf JG, Hyldstrup L. Osteocalcin: A non-invasive index of metabolic bone disease in patients treated by CAPD. *Kidney Int* 1994;46:838-846.
593. Gambacciani M, Spinetti A, Cappagli B, et al. Hormone replacement therapy in perimenopausal women with a low dose oral contraceptive preparation: Effects on bone mineral density and metabolism. *Maturitas* 1994;19:125-131.
594. Olmos JM, Pérez-Castrillón JL, García MT, Garrido JC, Amado JA, González-Macías J. Bone densitometry and biochemical bone remodeling markers in type I diabetes mellitus. *Bone Miner* 1994;26:1-8.
597. Nielsen HK, Brixen K, Mosekilde L. Diurnal rhythm in serum activity of wheat-germ lectin-precipitable alkaline phosphatase: Temporal relationships with the diurnal rhythm of serum osteocalcin. *Scand J Clin Lab Invest* 1990;50:851-856.
598. Mayne PD, Thakrar S, Rosalki SB, Foo AY, Parbhoo S. Identification of bone and liver metastases from breast cancer by measurement of plasma alkaline phosphatase isoenzyme activity. *J Clin Pathol* 1987;40:398-403.
599. Rodin A, Duncan A, Quartero HWP, et al. Serum concentrations of alkaline phosphatase isoenzymes and osteocalcin in normal pregnancy. *J Clin Endocrinol Metab* 1989;68:1123-1127.
600. Cimmino MA, Accardo S. Changes in the isoenzyme pattern of alkaline phosphatase in patients with rheumatoid arthritis. *Clin Chem* 1990;36:1376-1377.
601. Okesina AB, Donaldson D, Lascelles PT. Isoenzymes of alkaline phosphatase in epileptic patients receiving carbamazepine monotherapy. *J Clin Pathol* 1991;44:480-482.
608. Kollerup G, Sorenson HA, Storm T, Hyldstrup L. Urinary excretion of deoxypyridinoline during treatment with pamidronate in post-menopausal osteoporosis. *International Conference on Progress in Bone and Mineral Research, Vienna, Austria, October 14-16 1994*; (abst)
625. Blumsohn A, Herrington K, Hannon RA, Shao P, Eyre DR, Eastell R. The effect of calcium supplementation on the circadian rhythm of bone resorption. *J Clin Endocrinol Metab* 1994;79:730-735.
626. Garnero P, Gineys E, Riou JP, Delmas PD. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. *J Clin Endocrinol Metab* 1994;79:780-785.
627. Bell JL, Thompson C, Brown AJ, Dandona P. Total alkaline phosphatase and quantitative isoenzyme analysis in diabetes mellitus. *Ann Clin Biochem* 1988;25(Suppl.):93s-94s.
628. Tzoufi M, Siamopoulou-Mavridou A, Challa A, Lapatsanis PD. Changes of mineral metabolism in juvenile chronic arthritis. *Acta Paediatr* 1994;83 Suppl. 394:52-57.
630. Lorente JA, Morote J. Behavior of bone alkaline phosphatase (BAP) determined with immunoradiometric assay in metastatic prostate cancer [letter]. *Int J Biol Markers* 1994;9:145.
648. Karlsson R, Edén S, Eriksson L, Von Schoultz B. Osteocalcin 24-hour profiles during normal pregnancy. *Gynecol Obstet Invest* 1992;34:197-201.
649. Terzolo M, Piovesan A, Osella G, et al. Serum levels of bone GLA protein (osteocalcin, BGP) and carboxyterminal propeptide of type I procollagen (PICP) in acromegaly: Effects of long-term octreotide treatment. *Calcif Tissue Int* 1993;52:188-191.
650. Kröger H, Risteli J, Risteli L, Penttilä I, Alhava E. Serum osteocalcin and carboxyterminal propeptide of type I procollagen in rheumatoid arthritis. *Ann Rheum Dis* 1993;52:338-342.
651. Åkesson K, Ljunghall S, Gärdsell P, Sernbo I, Obrant KJ. Serum osteocalcin and fracture susceptibility in elderly women. *Calcif Tissue Int* 1993;53:86-90.
653. Li F, Pitt PI, Sherwood R, et al. Biochemical markers of bone turnover in women with surgically treated carcinoma of the breast. *Eur J Clin Invest* 1993;23:566-571.
656. Gallacher SJ, Deighan C, Wallace AM, et al. Association of severe haemophilia A with osteoporosis: A densitometric and biochemical study. *Q J Med* 1994;87:181-186.
661. Juul A, Pedersen SA, Sorensen S, et al. Growth hormone (GH) treatment increases serum insulin-like growth factor binding protein-3, bone isoenzyme alkaline phosphatase and forearm bone mineral content in young adults with GH deficiency of childhood onset. *Eur J Endocrinol* 1994;131:41-49.
662. Frevert EU, Biester A, Müller MJ, Schmidt-Gayk H, Von zur Mühlen A, Brabant G. Markers of bone metabolism during short-term administration of thyroxine in healthy volunteers. *Eur J Endocrinol* 1994;131:145-149.
664. Johansen JS, Molholm Hansen JE, Christiansen C. A radioimmunoassay for bone Gla protein (BGP) in human plasma. *Acta Endocrinol* 1987;114:410-416.
665. Johansen JS, Riis BJ, Delmas PD, Christiansen C. Plasma BGP: An indicator of spontaneous bone loss and of the effect of oestrogen treatment in postmenopausal women. *Eur J Clin Invest* 1988;18:191-195.
666. Delmas PD, Chatelain P, Malaval L, Bonne G. Serum bone gla-protein in growth hormone deficient children. *J Bone Miner Res* 1986;1:333-337.
667. Brown JP, Malaval L, Chapuy MC, Delmas PD, Douard C, Meunier PJ. Serum bone gla-protein: A specific marker for bone formation in postmenopausal osteoporosis. *Lancet* 1984;1091-1093.
668. Kruse K, Kracht U. Evaluation of serum osteocalcin as an index of altered bone metabolism. *Eur J Pediatr* 1986;145:27-33.
669. Godschalk MF, Downs RW. Effect of short-term glucocorticoids on serum osteocalcin in healthy young men. *J Bone Miner Res* 1988;3:113-115.
670. Montecucco C, Baldi F, Fortina A, et al. Serum osteocalcin (bone Gla-protein) following corticosteroid therapy in postmenopausal women with rheumatoid arthritis. Comparison of the effect of prednisone and deflazacort. *Clin Rheumatol* 1988;7:366-371.
671. Pietschmann P, Knoflach P, Woloszczuk W. Increased serum osteocalcin levels in patients with lactase deficiency. *Am J Gastroenterol* 1991;86:72-74.
672. Laitinen K, Lamberg-Allardt C, Tunninen R, Härkönen M, Välimäki M. Bone mineral density and abstinence-induced changes in bone and mineral metabolism in noncirrhotic male alcoholics. *Am J Med* 1992;93:642-650.
673. Pedrazzoni M, Vescovi PP, Maninetti L, et al. Effects of chronic heroin abuse on bone and mineral metabolism. *Acta Endocrinol (Copenh)* 1993;129:42-45.

675. Rossini M, Gatti D, Zamberlan N, Braga V, Dorizzi R, Adami S. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. *J Bone Miner Res* 1994;9:1833-1837.
676. Szulc P, Arlot M, Chapuy M-C, Duboeuf F, Meunier PJ, Delmas PD. Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women. *J Bone Miner Res* 1994;9:1591-1595.
678. Branca F, Robins SP, Ferro-Luzzi A, Golden MHN. Bone turnover in malnourished children. *Lancet* 1992;340:1493-1495.
681. Kikuchi K, Sato S, Kadono T, Ihn H, Takehara K. Serum concentration of procollagen type I carboxyterminal propeptide in localized scleroderma. *Arch Dermatol* 1994;130:1269-1272.
682. Sano M, Kushida K, Takahashi M, et al. Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis. *Br J Cancer* 1994;70:701-703.
690. Tibi L, Chhabra SC, Sweeting VM, Winney RJ, Smith AF. Multiple forms of alkaline phosphatase in plasma of hemodialysis patients. *Clin Chem* 1991;37:815-820.
695. Bernardo Noriega Y, Gilson G, Schmit P, et al. Urinary pyridinium cross-links: Markers of higher bone resorption in patients with malignant hematological disease. *International Symposium of the MASCC, Prague, Czech Republic, September 28-October 1 1994*; (abst)
696. Kamel S, Brazier M, Picard C, et al. Urinary excretion of pyridinoline crosslinks measured by immunoassay and HPLC techniques in normal subjects and in elderly patients with vitamin D deficiency. *Bone Miner* 1994;26:197-208.
697. Abbiati G, Arrigoni M, Frignani S, Longoni A, Bartucci F, Castiglioni C. Effect of salmon calcitonin on deoxypyridinoline (Dpyr) urinary excretion in healthy volunteers. *Calcif Tissue Int* 1994;55:346-348.
698. Sairanen S, Tähtelä R, Laitinen K, Karonen SL, Välimäki MJ. Nocturnal rise in markers of bone resorption is not abolished by bedtime calcium or calcitonin. *Calcif Tissue Int* 1994;55:349-352.
699. Gallacher SJ, Fraser WD, Owens OJ, et al. Changes in calcitropic hormones and biochemical markers of bone turnover in normal human pregnancy. *Eur J Endocrinol* 1994;131:369-374.
700. Minisola S, Piccioni AL, Rosso R, et al. Reduced serum levels of carboxy-terminal propeptide of human type I procollagen in a family with type I-A osteogenesis imperfecta. *Metabolism* 1994;43:1261-1265.
701. Obrant KJ, Merle B, Bejui J, Delmas PD. Serum bone-gla protein after fracture. *Clin Orthop Rel Res* 1990;258:300-303.
705. Välimäki MJ, Tähtelä R, Jones JD, Peterson JM, Riggs BL. Bone resorption in healthy and osteoporotic postmenopausal women: Comparison markers for serum carboxy-terminal telopeptide of type I collagen and urinary pyridinium cross-links. *Eur J Endocrinol* 1994;131:258-262.
708. Díaz Diego EMx, Guerrero R, De la Piedra C. Six osteocalcin assays compared. *Clin Chem* 1994;40:2071-2077.
709. Magnusson P, Löfman O, Larsson L. Determination of alkaline phosphatase isoenzymes in serum by high-performance liquid chromatography with post-column reaction detection. *J Chromatogr Biomed Appl* 1992;576:79-86.
710. Fonseca V, Epstein O, Gill DS, et al. Hyperparathyroidism and low serum osteocalcin despite vitamin D replacement in primary biliary cirrhosis. *J Clin Endocrinol Metab* 1987;64:873-877.
718. Osada K, Seishima M, Mori S, Takemura M, Noma A. Etretinate administration reduces serum propeptide of type I procollagen level in patients with psoriasis. *Br J Dermatol* 1994;131:655-659.
719. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. *J Clin Endocrinol Metab* 1994;79:1693-1700.
724. Sartorio A, Conti A, Monzani M, Morabito F, Faglia G. Growth hormone treatment in adults with GH deficiency: Effects on new biochemical markers of bone and collagen turnover. *J Endocrinol Invest* 1993;16:893-898.
725. Piovesan A, Berruti A, Osella G, et al. Serum levels of carboxyterminal propeptide of type I procollagen in cancer patients with osteoblastic and osteolytic bone metastases. *Int J Biol Markers* 1994;9:243-246.
726. Kawana K, Kushida K, Takahashi M, et al. The effect of menopause on biochemical markers and ultrasound densitometry in healthy females. *Calcif Tissue Int* 1994;55:420-425.
727. Giannini S, Nobile M, Sartori L, et al. Bone density and mineral metabolism in thyroidectomized patients treated with long-term L-thyroxine. *Clin Sci* 1994;87:593-597.
729. Yasuda M, Kurabayashi T, Yamamoto Y, Fujimaki T, Oda K, Tanaka K. Effect of hormone replacement therapy on bone and lipid metabolism in women oophorectomized for the treatment of gynecologic malignancies. *Int J Gynecol Obstet* 1994;47:151-156.
731. Massey LK, Bergman EA, Wise KJ, Sherrard DJ. Interactions between dietary caffeine and calcium on calcium and bone metabolism in older women. *J Am Coll Nutr* 1994;13:592-596.
732. Horowitz M, Wishart JM, Goh D, Morris HA, Need AG, Nordin BEC. Oral calcium suppresses biochemical markers of bone resorption in normal men. *Am J Clin Nutr* 1994;60:965-968.
733. Kitazawa R, Kimble RB, Vannice JL, Kung VT, Pacifici R. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. *J Clin Invest* 1994;94:2397-2406.
734. Carlson K, Simonsson B, Ljunghall S. Acute effects of high-dose chemotherapy followed by bone marrow transplantation on serum markers of bone metabolism. *Calcif Tissue Int* 1994;55:408-411.
735. Brahm H, Ljunggren, Larsson K, Lindh E, Ljunghall S. Effects of infusion of parathyroid hormone and primary hyperparathyroidism on formation and breakdown of type I collagen. *Calcif Tissue Int* 1994;55:412-416.
736. Schlemmer A, Hassager C, Pedersen BJ, Christiansen C. Posture, age, menopause, and osteopenia do not influence the circadian variation in the urinary excretion of pyridinium crosslinks. *J Bone Miner Res* 1994;9:1883-1888.
738. Štěpán JJ, Silinková-Máľková E, Havránek T, et al. Relationship of plasma tartrate resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism. *Clin Chim Acta* 1983;133:189-200.
739. Behr W, Barnert J. Quantification of bone alkaline phosphatase in serum by precipitation with wheat-germ lectin: A simplified method and its clinical plausibility. *Clin Chem* 1986;32:1960-1966.
749. Maugeri D, Panebianco P, Russo MS, et al. Ipriflavone-treatment of senile osteoporosis: Results of a multicenter, double-blind clinical trial of 2 years. *Arch Gerontol Geriatr* 1994;19:253-263.
751. Garton M, Reid I, Loveridge N, et al. Bone mineral density and metabolism in premenopausal women taking L-thyroxine replacement therapy. *Clin Endocrinol (Oxf)* 1994;41:747-755.
758. Sorva A, Välimäki M, Risteli J, et al. Serum ionized calcium, intact PTH and novel markers of bone turnover in bedridden elderly patients. *Eur J Clin Invest* 1994;24:806-812.
760. Pecherstorfer M, Zimmer-Roth I, Schilling T, et al. The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. *J Clin Endocrinol Metab* 1995;80:97-103.

761. Giustina A, Bussi AR, Jacobello C, Wehrenberg WB. Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone. *J Clin Endocrinol Metab* 1995;80:122-129.
766. Cantatore FP, Cincinelli E, Galantino P, et al. Evaluation of bone turnover and bone mass during tapering estrogen therapy: A preliminary report. *Arthritis Rheum* 1995;38:292-294.
768. Spector TD, James IT, Hall GM, Thompson PW, Perrett D, Hart DJ. Increased levels of urinary collagen crosslinks in females with rheumatoid arthritis. *Clin Rheumatol* 1993;12:240-244.
769. Thompson PW, Spector TD, James IT, Henderson E, Hart DJ. Urinary collagen crosslinks reflect the radiographic severity of knee osteoarthritis. *Br J Rheumatol* 1992;31:759-761.
770. MacDonald AG, McHenry P, Robins SP, Reid DM. Relationship of urinary pyridinium crosslinks to disease extent and activity in osteoarthritis. *Br J Rheumatol* 1994;33:16-19.
771. Astbury C, Bird HA, McLaren AM, Robins SP. Urinary excretion of pyridinium crosslinks of collagen correlated with joint damage in arthritis. *Br J Rheumatol* 1994;33:11-15.
772. Pecherstorfer M, Seibel MJ, Schuster J, Buck S, Zimmer-Roth I, Ludwig H. Differentiation between monoclonal gammopathy of undetermined significance and multiple myeloma by biochemical parameters of bone metabolism. *American Association for Cancer Research, Toronto, Canada, March 18-22 1995*:(abst)
773. Civitelli R, Gonnelli S, Zacchei F, et al. Bone turnover in postmenopausal osteoporosis: Effect of calcitonin treatment. *J Clin Invest* 1988;82:1268-1274.
774. Eastell R, Delmas PD, Hodgson SF, Eriksen EF, Mann KG, Riggs BL. Bone formation rate in older normal women: Concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers. *J Clin Endocrinol Metab* 1988;67:741-748.
775. Kelly PJ, Pocock NA, Sambrook PN, Eisman JA. Age and menopause-related changes in indices of bone turnover. *J Clin Endocrinol Metab* 1989;69:1160-1165.
776. Van Hoof VO, Hoylaerts MF, Geryl H, Van Mullem M, Lepoutre LG, De Broe ME. Age and sex distribution of alkaline phosphatase isoenzymes by agarose electrophoresis. *Clin Chem* 1990;36:875-878.
777. McLaren AM, Isdale AH, Whiting PH, Bird HA, Robins SP. Physiological variation in the urinary excretion of pyridinium crosslinks of collagen. *Br J Rheumatol* 1993;32:307-312.
779. Gavilanes EL, Parra EG, De la Piedra C, Caramelo C, Rapado A. Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure. *Miner Electrolyte Metab* 1994;20:259-264.
781. Rauch F, Seibel M, Woitge H, Kruse K, Schönau E. Increased urinary excretion of collagen crosslinks in girls with Ullrich-Turner syndrome. *Acta Paediatr* 1995;84:66-69.
782. Meeran K, Hattersley A, Burrin J, Shiner R, Ibbertson K. Oral and inhaled corticosteroids reduce bone formation as shown by plasma osteocalcin levels. *Am J Respir Crit Care Med* 1995;151:333-336.
783. Sinigaglia L, Varena M, Binelli L, et al. Urinary and synovial pyridinium crosslink concentrations in patients with rheumatoid arthritis and osteoarthritis. *Ann Rheum Dis* 1995;54:144-147.
784. Karlsson MK, Vergnaud P, Delmas PD, Obrant KJ. Indicators of bone formation in weight lifters. *Calcif Tissue Int* 1995;56:177-180.
785. Bouman AA, Scheffer PG, Ooms ME, Lips P, Netelenbos C. Two bone alkaline phosphatase assays compared with osteocalcin as a marker of bone formation in healthy elderly women. *Clin Chem* 1995;41:196-199.
786. Blumsohn A, Hannon RA, Eastell R. Apparent instability of osteocalcin in serum as measured with different commercially available immunoassays. *Clin Chem* 1995;41:318-319.
787. Cooper EH, Whelan P, Purves D. Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer. *Prostate* 1994;25:236-242.
788. Shen V, Birchman R, Xu R, Lindsay R, Dempster DW. Short-term changes in histomorphometric and biochemical turnover markers and bone mineral density in estrogen- and/or dietary calcium-deficient rats. *Bone* 1995;16:149-156.
789. Alvarez L, Guañabens N, Peris P, et al. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. *J Bone Miner Res* 1995;10:458-465.
791. Anderson FH, Francis RM, Peatson RT. Androgen therapy in eugonadal men with osteoporosis: Effects of six months' treatment on markers of bone formation and resorption. *J Endocrinol* 1995;144(Suppl.):P21. (abst)
792. Hannon RR, Blumsohn A, Al-Dehaimi AW, Eastell R. The use of biochemical markers to monitor the skeletal response to hormone replacement therapy. *Bone* 1995;16(1, Suppl.):109S. (abst)
794. Traverso A, Boccigone E, Tanganelli P, Regesta G, Ottonello GA, Giordano G. Bone resorption in epileptic patients on chronic treatment assessed by the measurement of urinary pyridinium crosslinks and urinary crosslinked N-telopeptides of bone type I collagen. *Bone* 1995;16(1, Suppl.):108S. (abst)
798. Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone crosslinks excretion. *J Bone Miner Res* 1995;10:641-649.
800. Blumsohn A, Colwell A, Naylor K, Eastell R. Effect of light and gamma irradiation on pyridinoline and telopeptides of type I collagen in urine. *Clin Chem* 1995;41:1195-1197.
803. Scott D, Abu Damir H, Buchan W, Duncan A, Robins SP. Factors affecting urinary pyridinoline and deoxypyridinoline excretion in the growing lamb. *Bone* 1993;14:807-811.
805. Cross NA, Hillman LS, Allen SH, Krause GF, Vieira NE. Calcium homeostasis and bone metabolism during pregnancy, lactation, and postweaning: A longitudinal study. *Am J Clin Nutr* 1995;61:514-523.
806. Díez J, Laviades C, Mayor G, Gil MJ, Monreal I. Increased serum concentrations of procollagen peptides in essential hypertension: Relation to cardiac alterations. *Circulation* 1995;91:1450-1456.
807. Van Papendorp DH, Coetzer H, Kruger MC. Biochemical profile of osteoporotic patients on essential fatty acid supplementation. *Nutr Res* 1995;15:325-334.
808. Polito C, Strano CG, Rea L, et al. Reduced bone mineral content and normal serum osteocalcin in non-steroid-treated patients with juvenile rheumatoid arthritis. *Ann Rheum Dis* 1995;54:193-196.
809. Kleerekoper M. Extensive personal experience: The clinical evaluation and management of osteoporosis. *J Clin Endocrinol Metab* 1995;80:757-763.
810. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): Follow-up on hormone replacement therapy and osteoporosis risk assessment. *J Clin Endocrinol Metab* 1995;80:864-868.
811. Beshyah SA, Kyd P, Thomas E, Fairney A, Johnston DG. The effects of prolonged growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults. *Clin Endocrinol (Oxf)* 1995;42:249-254.
812. Díaz Diego EM, Díaz Martín MA, De la Piedra C, Rapado A. Lack of correlation between levels of osteocalcin and bone alkaline phosphatase in healthy control and postmenopausal osteoporotic women. *Horm Metab Res* 1995;27:151-154.
813. Weiler HA, Wang Z, Atkinson SA. Dexamethasone treatment impairs calcium regulation and reduces bone mineralization in infant pigs. *Am J Clin Nutr* 1995;61:805-811.

814. Reale MG, Santini D, Marchei GG, et al. Skeletal alkaline phosphatase as a serum marker of bone metastases in the follow-up of patients with breast cancer. *Int J Biol Markers* 1995;10:42-46.
815. Gerrits MI, Thijssen JHH, Van Rijn HJM. Determination of pyridinoline and deoxypyridinoline in urine, with special attention to retaining their stability. *Clin Chem* 1995;41:571-574.
816. Wolthers OD, Juul A, Hansen M, Müller J, Pedersen S. The insulin-like growth factor axis and collagen turnover in asthmatic children treated with inhaled budesonide. *Acta Paediatr* 1995;84:393-397.
817. Cheung CK, Panesar NS, Lau E, Woo J, Swaminathan R. Increased bone resorption and decreased bone formation in Chinese patients with hip fracture. *Calcif Tissue Int* 1995;56:347-349.
818. La Montagna G, Baruffo A, Abbadessa S, Maja L, Tirri R. Evidence for bone resorption in systemic sclerosis [letter]. *J Rheumatol* 1995;22:797-799.
819. Crofton PM, Stirling HF, Kelnar CJH. Bone alkaline phosphatase and height velocity in short normal children undergoing growth-promoting treatments: Longitudinal study. *Clin Chem* 1995;41:672-678.
840. Cosman F, Nieves J, Shen V, Lindsay R. Oral 1,25-dihydroxyvitamin D administration in osteoporotic women: Effect of estrogen therapy. *J Bone Miner Res* 1995;10:594-600.
842. Price CP, Thompson PW. The role of biochemical tests in the screening and monitoring of osteoporosis. *Ann Clin Biochem* 1995;32:244-260.
845. Blumsohn A, Naylor KE, Assiri AMA, Eastell R. Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease. *Clin Chem* 1995;41:1592-1598.
846. Cosman F, Nieves J, Herbert J, Shen V, Lindsay R. High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. *J Bone Miner Res* 1994;9:1097-1105.
853. Body JJ, Dumon JC, Mendes da Costa M, Lumen MA. Biochemical dose-response effects of pamidronate in postmenopausal osteoporosis - evaluation of new markers of bone resorption. *Calcif Tissue Int* 1995;56:481. (abst)
854. Hannon RA, Blumsohn A, Smith TWD, Eastell R. Changes in biochemical markers of bone turnover during fracture healing. *Calcif Tissue Int* 1995;56:483. (abst)
855. Bijlsma JWJ, Lems WF, Gerrits MI, Jacobs JWJ, van Vugt RM, Van Rijn HJM. Effect of high-dose corticosteroid pulse therapy on (markers of) bone formation and resorption in rheumatoid arthritis. *Calcif Tissue Int* 1995;56:500. (abst)
858. Suquía B, Querol R, Breñas MT, et al. Behaviour of bone remodeling markers in Paget's disease. *Calcif Tissue Int* 1995;56:504. (abst)
861. Price CP. Multiple forms of human serum alkaline phosphatase: detection and quantitation. *Ann Clin Biochem* 1993;30:355-372.
862. Nielsen HK, Brixen K, Bouillon R, Mosekilde L. Changes in biochemical markers of osteoblastic activity during the menstrual cycle. *J Clin Endocrinol Metab* 1990;70:1431-1437.
866. Price CP, Park HR, Milligan T. Characteristics of a capture immunoassay for bone alkaline phosphatase. *Clin Chem* 1995;41:S232. (abst)
869. Garton M, Martin J, Stewart A, et al. Changes in bone mass and metabolism after surgery for primary hyperparathyroidism. *Clin Endocrinol (Oxf)* 1995;42:493-500.
870. Wollmann HA, Schönau E, Blum WF, Meyer F, Kruse K, Ranke MB. Dose-dependent responses in insulin-like growth factors, insulin-like growth factor-binding protein-3 and parameters of bone metabolism to growth hormone therapy in young adults with growth hormone deficiency. *Horm Res* 1995;43:249-256.
871. Lisá L, Neradilová M, Tomášová N, Soutorová M, Zimák J. Osteocalcin in congenital adrenal hyperplasia. *Bone* 1995;16:57-59.
873. Niwa T, Shiobara K, Hamada T, et al. Serum pyridinolines as specific markers of bone resorption in hemodialyzed patients. *Clin Chim Acta* 1995;235:33-40.
874. Hata K, Miura M, Fukumoto S, Matsumoto T. Assay of serum pyridinoline: A potential marker for bone resorption. *Clin Chim Acta* 1995;235:221-227.
875. Fujimoto S, Kubo T, Tanaka H, Miura M, Seino Y. Urinary pyridinoline and deoxypyridinoline in healthy children and in children with growth hormone deficiency. *J Clin Endocrinol Metab* 1995;80:1922-1928.
876. Shaw NJ, Dutton J, Fraser WD, Smith CS. Urinary pyridinoline and deoxypyridinoline excretion in children. *Clin Endocrinol (Oxf)* 1995;42:607-612.
877. Ricard-Blum S, Chevalier X, Grimaud JA, Larget-Piet B, Uebelhart D. Detectable levels of pyridinoline are present in synovial fluid from various patients with knee effusion: Preliminary results. *Eur J Clin Invest* 1995;25:438-441.
878. Pedrazzoni M, Alfano FS, Gatti C, et al. Acute effects of bisphosphonates on new and traditional markers of bone resorption. *Calcif Tissue Int* 1995;57:25-29.
879. Beyeler C, Banks RE, Thompson D, Forbes MA, Cooper EH, Bird H. Bone alkaline phosphatase in rheumatic diseases. *Ann Clin Biochem* 1995;32:379-384.
880. Durham BH, Robinson J, Fraser WD. Differences in the stability of intact osteocalcin in serum, lithium heparin plasma and EDTA plasma. *Ann Clin Biochem* 1995;32:422-423.
885. Michalsky M, Stepan JJ, Wilczek H, Formankova J, Moro L. Galactosyl hydroxylysine in assessment of Paget's bone disease. *Clin Chim Acta* 1995;234:101-108.
897. Uebelhart D, Demiaux-Domenech B, Roth M, et al. Prospective evolution of biochemical markers of bone metabolism and whole-body composition in spinal cord injury patients. *J Bone Miner Res* 1995;10(suppl.1):S181. (abst)
898. McClure L, Gross C, Villa ML, et al. Vitamin D receptor alleles, bone mineral density, and bone metabolism in elderly Mexican-American women. *J Bone Miner Res* 1995;10(suppl.1):S189. (abst)
899. Fisher JE, Gentile M, Rodan SB, Jenkins D, Rodan GA. Urinary deoxypyridinoline measurements, by enzyme-linked immunosorbent assay, correlate with bone loss caused by ovariectomy in 6 month old rats. *J Bone Miner Res* 1995;10(suppl.1):S242. (abst)
900. McRae GI, Tallentire D, Zuber Y, Kimmel DB, Avnur Z, Vickery BH. Ovariectomy causes rapid, but not completely maintained, bone loss in young cynomolgous macaques. *J Bone Miner Res* 1995;10(suppl.1):S247. (abst)
901. Holloway L, Kohlmeier L, Marcus R. Effects of cyclic recombinant human growth hormone and salmon calcitonin on bone mineral density and bone turnover in postmenopausal women. *J Bone Miner Res* 1995;10(suppl.1):S253. (abst)
902. Prestwood KM, Pilbeam CC, Fall PM, Raisz LG. Low dose conjugated estrogen reduces biochemical markers of bone turnover in older women. *J Bone Miner Res* 1995;10(suppl.1):S256. (abst)
904. Yamamoto I, Tazaki M, Yuu I, Morita R. Mass screening for osteopenia using ultra-sound assessment of the calcaneus and measuring urinary deoxypyridinoline. *J Bone Miner Res* 1995;10(suppl.1):S271. (abst)
906. Shapiro JR, Copley C, Goldsborough D, Gelman R, Barnhart K. Effect of pamidronate on bone turnover and IGF-I in type I osteogenesis imperfecta. *J Bone Miner Res* 1995;10(suppl.1):S301. (abst)
907. Sacco-Gibson N, Lowry C, Smith J, et al. Bone marker changes in etidronate or estrogen-treated postmenopausal women are similar. *J Bone Miner Res* 1995;10(suppl.1):S351. (abst)
908. Kleerekoper M, Parikh N, Parfitt AM. Comparison of three methods for bone specific alkaline phosphatase. *J Bone Miner Res* 1995;10(suppl.1):S371. (abst)
909. Wang T, Leary ET. Comparison of a new enzyme immunoassay for bone alkaline phosphatase with an immunoradiometric and an electrophoretic method. *J Bone Miner Res* 1995;10(suppl.1):S403. (abst)

910. Van Hoof VO, Jansen H, Schepens P, et al. Comparison of three methods to quantify serum bone alkaline phosphatase. *J Bone Miner Res* 1995;10(suppl.1):S419. (abst)
911. Bhandari V, Fall P, Rowe JC, Raisz L. C-terminal type I collagen propeptide and bone specific alkaline phosphatase levels in preterm infants: Potential growth markers? *J Bone Miner Res* 1995;10(suppl.1):S440. (abst)
912. DePriest SG, Cerelli MJ, To W-L, et al. The effect of day-to-day and diurnal variation on two immunoassays for pyridinium crosslinks in urine. *J Bone Miner Res* 1995;10(suppl.1):S473. (abst)
913. Stempfle HU, Birner H, Ellinger M, et al. Free pyridinoline crosslinks predict early bone loss after heart transplantation. *J Bone Miner Res* 1995;10(suppl.1):S479. (abst)
914. Gomez B, Jr., Ardakani S, Ju J, et al. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. *Clin Chem* 1995;41:1560-1566.
915. Roux JP, Arlot ME, Gineys E, Meunier PJ, Delmas PD. Automatic-interactive measurement of resorption cavities in transiliac bone biopsies and correlation with deoxypyridinoline. *Bone* 1995;17:153-156.
916. Erdtsieck RJ, Pols HAP, Valk NK, et al. Treatment of postmenopausal osteoporosis with a combination of growth hormone and pamidronate. A placebo controlled trial. *Clin Endocrinol* 1995;43:557-565.
917. Clarke BL, Muhs JM, O'Connell MJ, McCarthy JT, O'Fallon WM, Riggs BL. Assessment of bone resorption in metabolic bone disorders using a new enzyme immunoassay for urinary free pyridinoline: Comparison with standard methods of assessment of bone formation. *Endocrine Practice* 1995;1:248-256.
918. Smith J, Shoukri K, Trahiotis M, et al. Bone marker changes in risedronate-treated postmenopausal women. *J Bone Miner Res* 1995;10(Suppl.1):S351. (abst)
919. Kenny AM, Prestwood KM, Fall P, Woodiel F, Raisz LG. Different effects of estrogen, tamoxifen, and calcium on the excretion of crosslinks in older women. *J Bone Miner Res* 1995;10(Suppl.1):S368. (abst)
920. Åkesson K, Vergnaud P, Delmas PD, Obrant KJ. Serum osteocalcin increases during fracture healing in elderly women with hip fracture. *Bone* 1995;16:427-430.
921. Santi I, Monti M, Viganò A, et al. Serum levels of procollagen type I carboxyterminal extension peptide in cancer patients with bone metastases. *Int J Biol Markers* 1995;10:107-112.
922. Sone T, Fukunaga M, Ono S, Nishiyama T. A small dose of human parathyroid hormone(1-34) increased bone mass in the lumbar vertebrae in patients with senile osteoporosis. *Miner Electrolyte Metab* 1995;21:232-235.
923. Hall GM, Spector TD, Delmas PD. Markers of bone metabolism in postmenopausal women with rheumatoid arthritis: Effects of corticosteroids and hormone replacement therapy. *Arthritis Rheum* 1995;38:902-906.
924. Michaëlsson K, Holmberg L, Mallmin H, Wolk A, Bergström R, Ljunghall S. Diet, bone mass, and osteocalcin: A cross-sectional study. *Calcif Tissue Int* 1995;57:86-93.
925. Gorai I, Chaki O, Nakayama M, Minaguchi H. Urinary biochemical markers for bone resorption during the menstrual cycle. *Calcif Tissue Int* 1995;57:100-104.
926. Reeve J, Pearson J, Mitchell A, et al. Evolution of spinal bone loss and biochemical markers of bone remodeling after menopause in normal women. *Calcif Tissue Int* 1995;57:105-110.
927. Çakatay U, Akçay T, Hacibekiroglu M, Ilkova H, Telci A. Variations in serum osteocalcin levels in diabetic subjects. *Med Sci Res* 1995;23:489-491.
928. Grinspoon SK, Baum HBA, Peterson S, Klibanski A. Effects of rhIGF-I administration on bone turnover during short-term fasting. *J Clin Invest* 1995;96:900-906.
929. Lieuw-A-Fa M, Sierra RI, Specker BL. Carboxy-terminal propeptide of human type I collagen and pyridinium cross-links as markers of bone growth in infants 1 to 18 months of age. *J Bone Miner Res* 1995;10:849-853.
930. Ureña P, Ferreira A, Kung VT, et al. Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. *J Bone Miner Res* 1995;10:932-939.
931. Kushida K, Takahashi M, Kawana K, Inoue T. Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients. *J Clin Endocrinol Metab* 1995;80:2447-2450.
932. Sokoll LJ, O'Brien ME, Camilo ME, Sadowski JA. Undercarboxylated osteocalcin and development of a method to determine vitamin K status. *Clin Chem* 1995;41:1121-1128.
933. Sowers M, Eyre D, Hollis BW, et al. Biochemical markers of bone turnover in lactating and nonlactating postpartum women. *J Clin Endocrinol Metab* 1995;80:2210-2216.
934. Fujiyama K, Kiriyma T, Ito M, et al. Attenuation of postmenopausal high turnover bone loss in patients with hypoparathyroidism. *J Clin Endocrinol Metab* 1995;80:2135-2138.
935. Hunt AH, Civitelli R, Halstead L. Evaluation of bone resorption: A common problem during impaired mobility. *SCI Nursing* 1995;12:90-94.
936. Charles P, Mosekilde L, Risteli L, Risteli J, Eriksen EF. Assessment of bone remodeling using biochemical indicators of type I collagen synthesis and degradation: Relation to calcium kinetics. *Bone Miner* 1994;24:81-94.
937. Joerring S, Krogsgaard M, Wilbek H, Jensen LT. Collagen turnover after tibial fracture. *Arch Orthop Trauma Surg* 1994;113:334-336.
938. Kylmälä T, Tammela T, Risteli L, Risteli J, Taube T, Elomaa I. Evaluation of the effect of oral clodronate on skeletal metastases with type I collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. *Eur J Cancer* 1993;29A:821-825.
939. Power MJ, O'Dwyer B, Breen E, Fottrell PF. Osteocalcin concentrations in plasma prepared with different anticoagulants. *Clin Chem* 1991;37:281-284.
940. Silverberg SJ, Gartenberg F, Jacobs TP, et al. Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. *J Clin Endocrinol Metab* 1995;80:723-728.
941. Silverberg SJ, Gartenberg F, Jacobs TP, et al. Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. *J Clin Endocrinol Metab* 1995;80:729-734.
942. Ooms ME, Roos JC, Bezemer PD, van der Vijgh WJF, Bouter LM, Lips P. Prevention of bone loss by vitamin D supplementation in elderly women: A randomized double-blind trial. *J Clin Endocrinol Metab* 1995;80:1052-1058.
943. Uebelhart D, Hartmann D, Vuagnat H, Castanier M, Hachen H-J, Chantraine A. Early modifications of biochemical markers of bone metabolism in spinal cord injury patients. A preliminary study. *Scand J Rehab Med* 1994;16:197-202.
944. Cannella G, Bonucci E, Rolla D, et al. Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol. *Kidney Int* 1994;46:1124-1132.
945. Mazzaferro S, Pasquali M, Ballanti P, et al. Diagnostic value of serum peptides of collagen synthesis and degradation in dialysis renal osteodystrophy. *Nephrol Dial Transplant* 1995;10:52-58.
946. Hamdy NAT, Risteli J, Risteli L, et al. Serum type I procollagen peptide: a non-invasive index of bone formation in patients on haemodialysis? *Nephrol Dial Transplant* 1994;9:511-516.

955. Rubini G, Anelli F, Correale M, Lauriero F, Rubini D, D'Addabbo A. Renal osteodystrophy with hyperparathyroidism: the diagnostic value of intact parathormone, alkaline phosphatase, osteocalcin and procollagen. *J Nucl Biol Med* 1994;38:489-494.
956. Bianchi ML, Colantonio G, Campanini F, et al. Calcitriol and calcium carbonate therapy in early chronic renal failure. *Nephrol Dial Transplant* 1994;9:1595-1599.
959. Delmas PD. Biochemical markers for the assessment of bone turnover. In: Riggs BL, Melton LJ, III, eds. Osteoporosis: etiology, diagnosis, and management. 2nd ed. Philadelphia: Lippincott-Raven Publishers, 1995:319-333.
960. Van Hoof VO, De Broe ME. Interpretation and clinical significance of alkaline phosphatase isoenzyme patterns. *Crit Rev Clin Lab Sci* 1994;31:197-293.
962. Kamel S, Brazier M, Neri V, et al. Multiple molecular forms of pyridinoline cross-links excreted in human urine evaluated by chromatographic and immunoassay methods. *J Bone Miner Res* 1995;10:1385-1392.
963. Nguyen-Pamart M, Bonnetterre J, Hecquet B. Urinary excretion of deoxypyridinoline in patients with breast cancer. *Anticancer Res* 1995;15:1601-1603.
964. Withold W, Georgescu G, Khakzad H, Vosberg H, Mueller-Gaertner HW, Reinauer H. Efficacy of simultaneous determination of bone alkaline phosphatase mass concentration in serum and urinary excretion of pyridinium cross-links for detection of bone metastases. *Clin Biochem* 1995;28:511-517.
965. Walne AJ, James IT, Perrett D. The stability of pyridinium crosslinks in urine and serum [letter]. *Clin Chim Acta* 1995;240:95-97.
966. Chevalier X, Ricard-Blum S, Grimaud JA. Increase urinary level of pyridinoline and deoxypyridinoline crosslinks in rapid destructive osteoarthritis. *Arthritis Rheum* 1995;38(9, Suppl):S238. (abst)
967. Mroczkowski PJ, Harris RZ, Tsunoda SM, Benet LZ, Lane N. Hormone replacement therapy decreases the acute effects of prednisolone on bone formation in postmenopausal women. *Arthritis Rheum* 1995;38(9, Suppl):S392. (abst)
968. Elmlinger MW, Ackermann S, Wollmann HA, Heitz M, Ösme A, Ranke MB. Significance of bone specific alkaline phosphatase and procollagen-I-peptide as diagnostic markers of bone formation for monitoring growth hormone therapy. *German Society for Endocrinology "Congress on Calcium Regulating Hormones and Bone Metabolism", Giessen, Germany September 29-30 1995*; (abst)
970. Eisman JA, Christiansen C, McClung M, et al. Alendronate prevents bone loss at the spine and hip in recently postmenopausal women. *J Bone Miner Res* 1995;10(Suppl.1):S176. (abst)
971. Stock J, Bell N, Chesnut C, et al. Resolution of alendronate effects on bone turnover and BMD after multi-year treatment of osteoporotic women. *J Bone Miner Res* 1995;10(Suppl.1):S197. (abst)
972. Valk NK, Erdtsieck RJ, Algra D, Lamberts SWJ, Pols HAP. Combined treatment of growth hormone and the bisphosphonate pamidronate, versus treatment with GH alone, in GH-deficient adults: The effects on renal phosphate handling, bone turnover and bone mineral mass. *Clin Endocrinol (Oxf)* 1995;43:317-324.
974. Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nilssen MHL. The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate - Is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? *Bone* 1995;16:603-610.
975. Douglas AS, Robins SP, Hutchison JD, Porter RW, Stewart A, Reid DM. Carboxylation of osteocalcin in post-menopausal osteoporotic women following vitamin K and D supplementation. *Bone* 1995;17:15-20.
976. Segawa Y, Nakamura T, Aota S, et al. Changes in urinary deoxypyridinoline level and vertebral bone mass in the development of adjuvant-induced arthritis in rats. *Bone* 1995;17:57-62.
977. Pedersen BJ, Schlemmer A, Hassager C, Christiansen C. Changes in the carboxyl-terminal propeptide of type I procollagen and other markers of bone formation upon five days of bed rest. *Bone* 1995;17:91-95.
978. Letizia C, Minisola S, Cerci S, et al. Serum concentrations of osteocalcin in pregnant women with multinodular thyroid goiter undergoing treatment with levothyroxine. *Endocr Res* 1995;21:645-652.
979. Saggese G, Baroncelli GI, Bertelloni S, Perri G. Long-term growth hormone treatment in children with renal hypophosphatemic rickets: Effects on growth, mineral metabolism, and bone density. *J Pediatr* 1995;127:395-402.
980. Lotz J, Steeger D, Hafner G, Ehrental W, Heine J, Prellwitz W. Biochemical bone markers compared with bone density measurement by dual energy X-ray absorptiometry. *Calcif Tissue Int* 1995;57:253-257.
983. Demers LM, Costa L, Chinchilli VM, Gaydos L, Curley E, Lipton A. Biochemical markers of bone turnover in patients with metastatic bone disease. *Clin Chem* 1995;41:1489-1494.
985. Alatas O, Çolak O, Alatas E, Tekin B, Inal M, Özalp S. Osteocalcin metabolism in late fetal life: Fetal and maternal osteocalcin levels. *Clin Chim Acta* 1995;239:179-183.
987. Hermus AR, Smals AG, Swinkels LM, et al. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome. *J Clin Endocrinol Metab* 1995;80:2859-2865.
988. Ganu V, Doughty J, Spirito S, Goldberg R. Elevation of urinary pyridinoline in adjuvant arthritic rats and its inhibition by doxycycline. *Ann NY Acad Sci* 1994;732:416-418.
989. Greenwald RA, Moak SA, Golub LM. Low dose doxycycline inhibits pyridinoline excretion in selected patients with rheumatoid arthritis. *Ann NY Acad Sci* 1994;732:419-421.
990. Le Bourgeois M, Cormier C, Kindermans C, et al. Inhaled beclomethasone and bone metabolism in young asthmatic children: A six-month study. *J Allergy Clin Immunol* 1995;96:565-567.
991. Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. *N Engl J Med* 1994;331:1618-1623.
994. Lau K-HW, Nakade O, Barr B, Taylor AK, Houchin K, Baylink DJ. Phenytoin increases markers of osteogenesis for the human species in vitro and in vivo. *J Clin Endocrinol Metab* 1995;80:2347-2353.
996. Degerblad M, Bengtsson B-A, Brammert M, et al. Reduced bone mineral density in adults with growth hormone (GH) deficiency: Increased bone turnover during 12 months of GH substitution therapy. *Eur J Endocrinol* 1995;133:180-188.
997. Dumon JC, Body JJ. Circulating osteocalcin in hypercalcemic cancer patients: A comparative evaluation of two immunoassays. *Diagn Oncol* 1994;4:170-173.
999. Garnero P, Borel O, Sornay-Rendu E, Delmas PD. Vitamin D receptor gene polymorphisms do not predict bone turnover and bone mass in healthy premenopausal women. *J Bone Miner Res* 1995;10:1283-1288.
1000. Cross NA, Hillman LS, Allen SH, Krause GF. Changes in bone mineral density and markers of bone remodeling during lactation and postweaning in women consuming high amounts of calcium. *J Bone Miner Res* 1995;10:1312-1320.
1001. Gonzalez MT, Bonnin R, Cruzado JM, et al. Course of three biochemical bone markers after kidney transplantation. *Transplant Proc* 1995;27:2266-2271.
1002. Takahashi M, Kushida K, Inoue T. Receiver operating characteristic analysis of urinary pyridinium cross-links in arthritis [letter]. *Br J Rheumatol* 1995;34:792-793.
1004. Robins SP. Collagen crosslinks in metabolic bone disease. *Acta Orthop Scand* 1995;66(Suppl.266):171-175.
1005. Peel NFA, Barrington NA, Blumsohn A, Colwell A, Hannon R, Eastell R. Bone mineral density and bone turnover in spinal osteoarthritis. *Ann Rheum Dis* 1995;54:867-871.

1007. Shapses SA, Robins SP, Schwartz EI, Chowdhury H. Short-term changes in calcium but not protein intake alter the rate of bone resorption in healthy subjects as assessed by urinary pyridinium cross-link excretion. *J Nutr* 1995;125:2814-2821.
1008. Brazier M, Kamel S, Maamer M, et al. Markers of bone remodeling in the elderly subject: Effects of vitamin D insufficiency and its correction. *J Bone Miner Res* 1995;10:1753-1761.
1009. Åkesson K, Ljunghall S, Jonsson B, et al. Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: A retrospective and prospective population-based study of women. *J Bone Miner Res* 1995;10:1823-1829.
1011. Kubo T, Tanaka H, Inoue M, Kanzaki S, Seino Y. Serum levels of carboxyterminal propeptide of type I procollagen and pyridinoline crosslinked telopeptide of type I collagen in normal children and children with growth hormone (GH) deficiency during GH therapy. *Bone* 1995;17:397-401.
1012. Klein GL, Herndon DN, Goodman WG, et al. Histomorphometric and biochemical characterization of bone following acute severe burns in children. *Bone* 1995;17:455-460.
1014. Kenny AM, Prestwood KM, Pilbeam CC, Raisz LG. The short term effects of tamoxifen on bone turnover in older women. *J Clin Endocrinol Metab* 1995;80:3287-3291.
1018. Riggs BL, Melton LJ, III. The worldwide problem of osteoporosis: Insights afforded by epidemiology. *Bone* 1995;17:505S-511S.
1019. Ghiron LJ, Thompson JL, Holloway L, et al. Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women. *J Bone Miner Res* 1995;10:1844-1852.
1020. McKane WR, Khosla S, Burritt MF, et al. Mechanism of renal calcium conservation with estrogen replacement therapy in women in early postmenopause - A clinical research center study. *J Clin Endocrinol Metab* 1995;80:3458-3464.
1021. Dobnig H, Kainer F, Stepan V, et al. Elevated parathyroid hormone-related peptide levels after human gestation: Relationship to changes in bone and mineral metabolism. *J Clin Endocrinol Metab* 1995;80:3699-3707.
1023. Adami S, Passeri M, Ortolani S, et al. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. *Bone* 1995;17:383-390.
1025. Hata K, Tokuihiro H, Nakatsuka K, et al. Measurement of bone-specific alkaline phosphatase by an immunoselective enzyme assay method. *Ann Clin Biochem* 1996;33:127-131.
1026. Tokita A, Kelly PJ, Nguyen TV, et al. Genetic influences of type I collagen synthesis and degradation: Further evidence for genetic regulation of bone turnover. *J Clin Endocrinol Metab* 1994;78:1461-1466.
1027. Gerrits MI. Determination of pyridinoline and deoxypyridinoline in urine, with special attention to retaining their stability [letter]. *Klin Lab* 1995;41:937.
1028. Garnero P, Arden NK, Griffiths G, Delmas PD, Spector TD. Genetic influence on bone turnover in postmenopausal twins. *J Clin Endocrinol Metab* 1996;81:140-146.
1029. Chesnut CH, III, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. *Am J Med* 1995;99:144-152.
1030. Weser U, Etspüler H, Kaup Y. Enzymatic and immunological activity of 4000 years aged bone alkaline phosphatase. *FEBS Lett* 1995;375:280-282.
1031. Magnusson P, Häger A, Larsson L. Serum osteocalcin and bone and liver alkaline phosphatase isoforms in healthy children and adolescents. *Pediatr Res* 1995;38:955-961.
1034. Birkebaek NH, Esberg G, Andersen K, Wolthers O, Hassager C. Bone and collagen turnover during treatment with inhaled dry powder budesonide and beclomethasone dipropionate. *Arch Dis Child* 1995;73:524-527.
1036. Hashimoto K, Nozaki M, Inoue Y, Sano M, Nakano H. The chronological change of vertebral bone loss following oophorectomy using dual energy X-ray absorptiometry: The correlation with specific markers of bone metabolism. *Maturitas* 1995;22:185-191.
1039. Withold W, Degenhardt S, Grabensee B, Reinauer H. Comparison between serum levels of bone alkaline phosphatase and the carboxy-terminal propeptide of type I procollagen as markers of bone formation in patients following renal transplantation. *Clin Chim Acta* 1995;239:143-151.
1042. Raisz LG, Wiita B, Artis A, et al. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. *J Clin Endocrinol Metab* 1996;81:37-43.
1043. Johansson AG, Lindh E, Blum WF, Kollerup G, Sorensen OH, Ljunghall S. Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis. *J Clin Endocrinol Metab* 1996;81:44-48.
1044. Ikeda I, Miura T, Kondo I. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. *Br J Urol* 1996;77:102-106.
1045. van Daele PLA, Seibel MJ, Burger H, et al. Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study. *Br Med J* 1996;312:482-483.
1050. Gomez B, Jr., Ardakani S, Evans BJ, Merrell LD, Jenkins DK, Kung VT. Monoclonal antibody assay for free urinary pyridinium cross-links. *Clin Chem* 1996;42:1168-1175.
1051. Vickery BH, Bergstrom K, DeRosier A, Katigbak L, Waters RA. RS-66271 very rapidly reverses bone loss induced by prednisone in rabbits. *J Bone Miner Res* 1995;10(Suppl.1):S257. (abst)
1053. Devogelaer JP, Broll H, Correa-Rotter R, et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. *Bone* 1996;18:141-150.
1054. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. *J Bone Miner Res* 1996;11:337-349.
1055. Cheng S, Kovanen V, Heikkinen E, Suominen H. Serum and urine markers of type I collagen metabolism in elderly women with high and low bone mineral density. *Eur J Clin Invest* 1996;26:186-191.
1056. Blumsohn A, Naylor KE, Assiri AMA, Eastell R. Effect of etidronate therapy on bone turnover and bone density in mild Paget's disease. *Bone* 1995;17:608. (abst)
1057. Tamayo J, Rojas M, Altamirano E, Hung W-L, Jenkins D. Monitoring alendronate-treated postmenopausal women with an immunoassay for free deoxypyridinoline. *Osteoporosis Int* 1996;6(Suppl.1):S248. (abst)
1058. Hesley R, Shepard K, Jenkins D, Riggs BL. Free deoxypyridinoline levels are associated with bone loss in postmenopausal women. *Osteoporosis Int* 1996;6(Suppl.1):S184. (abst)
1061. Aloia JF, Vaswani A, Yeh JK, Russo L. Differential effects of dietary calcium augmentation and hormone replacement therapy on bone turnover and serum levels of calcitropic hormones. *Osteoporosis Int* 1996;6:55-62.
1064. Vaccaro F, Pagano A, Gioviale MC, et al. Diagnostic value of pyridinolinic urinary collagen cross-links in hyperparathyroidism of kidney transplant patients. *Dialysis & Transplantation* 1996;25:132-163.
1065. Roux C, Ravaud P, Cohen-Solal M, et al. Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. *Bone* 1994;15:41-49.
1066. Pedersen BJ, Schlemmer A, Rosenquist C, Hassager C, Christiansen C. Circadian rhythm in type I collagen formation in postmenopausal women with and without osteopenia. *Osteoporosis Int* 1995;5:472-477.

1067. Nakamura H, Mori T, Genma R, et al. Urinary excretion of pyridinoline and deoxypyridinoline measured by immunoassay in hypothyroidism. *Clin Endocrinol* 1996;44:447-451.
1068. Mitlak BH, Burdette-Miller P, Schoenfeld D, Neer RM. Sequential effects of chronic human PTH (1-84) treatment of estrogen-deficiency osteopenia in the rat. *J Bone Miner Res* 1996;11:430-439.
1069. Meng XW, Liang XG, Birchman R, et al. Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats. *J Bone Miner Res* 1996;11:421-429.
1070. Kleerekoper M, Edelson GW. Biochemical studies in the evaluation and management of osteoporosis: current status and future prospects. *Endocr Pract* 1996;2:13-19.
1071. Kobayashi S, Inoue S, Hosoi T, Ouchi Y, Shiraki M, Orimo H. Association of bone mineral density with polymorphism of the estrogen receptor gene. *J Bone Miner Res* 1996;11:306-311.
1072. Kaddam IMS, Iqbal SJ, Holland S, Wong M, Manning D. Comparison of serum osteocalcin with total and bone specific alkaline phosphatase and urinary hydroxyproline:creatinine ratio in patients with Paget's disease of bone. *Ann Clin Biochem* 1994;31:327-330.
1075. Robins SP, Seibel MJ, McLaren AM. Collagen markers in urine in human arthritis. In: Maroudas A, Kuettner K, eds. *Methods in cartilage research*. London: Academic Press Ltd., 1990:348-352.
1076. Arnaud CD. Osteoporosis: Using 'bone markers' for diagnosis and monitoring. *Geriatrics* 1996;51:24-30.
1077. Cosman F, Nieves J, Wilkinson C, Schnering D, Shen V, Lindsay R. Bone density change and biochemical indices of skeletal turnover. *Calcif Tissue Int* 1996;58:236-243.
1080. Rosso R, Minisola S, Scarda A, et al. Temporal relationship between bone loss and increased bone turnover: A longitudinal study following natural menopause. *J Endocrinol Invest* 1995;18:723-728.
1081. Takahashi M, Hoshino H, Kushida K, Inoue T. Direct measurement of crosslinks, pyridinoline, deoxypyridinoline, and pentosidine, in the hydrolysate of tissues using high-performance liquid chromatography. *Anal Biochem* 1995;232:158-162.
1082. Bootsma GP, Dekhuijzen PNR, Festen J, Mulder PGH, Swinkels LMJW, Van Herwaarden CLA. Fluticasone propionate does not influence bone metabolism in contrast to beclomethasone dipropionate. *Am J Respir Crit Care Med* 1996;153:924-930.
1083. Falcini F, Trapani S, Ermini M, Brandi ML. Intravenous administration of alendronate counteracts the *in vivo* effects of glucocorticoids on bone remodeling. *Calcif Tissue Int* 1996;58:166-169.
1084. Mejjad O, Le Loët X, Basuyau JP, et al. Osteocalcin is not a marker of progress in multiple myeloma. *Eur J Haematol* 1996;56:30-34.
1085. Verhaeghe J, Van Herck E, Bouillon R. Umbilical cord osteocalcin in normal pregnancies and pregnancies complicated by fetal growth retardation or diabetes mellitus. *Biol Neonate* 1995;68:377-383.
1086. Bichler KH, Petri E, Hub A, Kleinknecht S, Heidenreich A. Investigations on bone metabolism of urological tumors forming metastases. *Urol Int* 1996;56:61-68.
1087. Guzzo C, Lazarus G, Goffe BS, Katz HI, Lowe NJ, Pincus SH. Topical calcipotriene has no short-term effect on calcium and bone metabolism of patients with psoriasis. *J Am Acad Dermatol* 1996;34:429-433.
1088. Campanello M, Herlitz H, Lindstedt G, et al. Bone mineral and related biochemical variables in patients with Kock ileal reservoir or Bricker conduit for urinary diversion. *J Urol* 1996;155:1209-1213.
1089. Lorente JA, Morote J, Raventos C, Encabo G, Valenzuela H. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. *J Urol* 1996;155:1348-1351.
1090. Bettica P, Taylor AK, Talbot J, Moro L, Talamini R, Baylink DJ. Clinical performances of galactosyl hydroxylysine, pyridinoline, and deoxypyridinoline in postmenopausal osteoporosis. *J Clin Endocrinol Metab* 1996;81:542-546.
1091. Nakayama K, Fukumoto S, Takeda S, et al. Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. *J Clin Endocrinol Metab* 1996;81:607-611.
1092. Yamaga A, Taga M, Minaguchi H, Sato K. Changes in bone mass as determined by ultrasound and biochemical markers of bone turnover during pregnancy and puerperium: A longitudinal study. *J Clin Endocrinol Metab* 1996;81:752-756.
1093. Withold W, Schulte U, Reinauer H. Method for determination of bone alkaline phosphatase activity: Analytical performance and clinical usefulness in patients with metabolic and malignant bone diseases. *Clin Chem* 1996;42:210-217.
1094. Thamsborg G, Jensen JEB, Kollerup G, Hauge EM, Melsen F, Sorensen OH. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis. *Bone* 1996;18:207-212.
1096. Ohta H, Sugimoto I, Masuda A, et al. Decreased bone mineral density associated with early menopause progresses for at least ten years: Cross-sectional comparisons between early and normal menopausal women. *Bone* 1996;18:227-231.
1097. Kraenzlin ME, Seibel MJ, Trechsel U, et al. The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: evidence of maximal effect after 8 weeks of continuous treatment. *Calcif Tissue Int* 1996;58:216-220.
1099. Garnero P, Chervet C, Delmas PD. Assessment of serum bone alkaline phosphatase activity with a new ELISA using monoclonal antibody. *Osteoporosis Int* 1996;6(Suppl.1):S189. (abst)
1100. van Daele PLA, Seibel MJ, Burger H, et al. Evidence for uncoupling of bone formation and bone resorption in women with hip fractures: a prospective study. *Osteoporosis Int* 1996;6(Suppl.1):S199. (abst)
1103. Reinhardt W, Bartelworth H, Jockenhövel F, et al. Sequential changes of biochemical bone parameters after kidney transplantation. *10th International Congress on Endocrinology, San Francisco, USA, June 12-15 1996*; (abst)
1105. Terano T, Shiina T, Tatsuno I, et al. Measurement of bone turnover in untreated Grave's hyperthyroidism and the effects of treatment. *10th International Congress on Endocrinology, San Francisco, USA, June 12-15 1996*; (abst)
1113. Garnero P, Hausherr E, Chapuy M-C, et al. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study. *J Bone Miner Res* 1996;11:1-8.
1115. Goulding A, Gold E, Lewis-Barned NJ. Effects of hysterectomy on bone in intact rats, ovariectomized rats, and ovariectomized rats treated with estrogen. *J Bone Miner Res* 1996;11:977-983.
1117. Isaksson P, Hannuniemi R, Österman T, Kuurtamo P, Laurén L, Sellman R. Effects of orally administered clodronate on biochemical markers of bone turnover in ovariectomized rats. *Osteoporosis Int* 1996;6(Suppl.1):264. (abst)
1118. Bradbeer JN, Stroup GB, Hoffman SJ, Lee JC, Gowen M. An orally active inhibitor of cytokine synthesis prevents bone loss in the ovariectomized rat. *J Bone Miner Res* 1996;11(Suppl.1):S125. (abst)
1119. Lane NE, Thompson JM, Haupt DL, Breunig T, Kinney JH. The early changes in osteoclast activity and trabecular connectivity in a rat model of estrogen deficiency. *J Bone Miner Res* 1996;11(Suppl.1):S218. (abst)
1120. Register TC, Jerome CP. Increased urinary markers of collagen degradation accompany ovariectomy in skeletally mature cynomolgus macaques. *J Bone Miner Res* 1996;11(Suppl.1):S196. (abst)

1121. Vanderschueren D, Van Herck E, De Coster R, Bouillon R. Aromatization of androgens is important for skeletal maintenance of aged male rats. *Calcif Tissue Int* 1996;59:179-183.
1129. Tobias JH, Laversuch CJ, Chambers TJ, Gallagher AC. Aminohexane bisphosphonate suppresses bone turnover in postmenopausal women more rapidly than oestrogen-gestagen therapy. *Br J Rheumatol* 1996;35:636-641.
1130. Randall AG, Kent GN, Garcia-Webb P, et al. Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links. *J Bone Miner Res* 1996;8:1176-1184.
1131. Chen S-Y, Sickle M, Kline S, Berard-Aubin J, Corkery J, Bluestein B. Rapid urinary deoxypyridinoline measurement by an automated immunoassay. *J Bone Miner Res* 1996;11:S191. (abst)
1132. Popp-Snijders C, Lips P, Netelenbos JC. Intra-individual variation in bone resorption markers in urine. *Ann Clin Biochem* 1996;33:347-348.
1135. Eastell R. Variability in bone biomarkers: how relevant for the clinical situation? *18th Annual Meeting of the American Society for Bone and Mineral Research, Seattle, USA, September 7-11 1996*; (abst)
1136. Visor J, Freeman K, Cerelli MJ, Stringer M, Liu V. An immunoassay for the quantitation of pyridinoline in serum. *J Bone Miner Res* 1996;11:S191. (abst)
1137. Withold W, Georgescu G, Khakzad H, Vosberg H, Mueller-Gaertner HM, Reinauer H. Simultaneous assessment of bone collagen synthesis and degradation in patients with different malignant tumours: comparison with the results of ^{99m}Tc-methylene bisphosphonate bone scintigraphy. *Eur J Clin Chem Clin Biochem* 1995;33:479-485.
1140. Tanaka Y, Nakamura T, Nishida S, et al. Effects of a synthetic Vitamin D analog, ED-71, on bone dynamics and strength in cancellous and cortical bone in prednisolone-treated rats. *J Bone Miner Res* 1996;11:325-336.
1141. Lane NE, Kimmel DB, Nilsson MHL, et al. Bone-selective analogs of human PTH(1-34) increase bone formation in an ovariectomized rat model. *J Bone Miner Res* 1996;11:614-625.
1142. Kippo K, Hannuniemi R, Virtamo T, et al. The effects of clodronate on increased bone turnover and bone loss due to ovariectomy in rats. *Bone* 1996;17:533-542.
1145. Woitge HW, Seibel MJ, Ziegler R. Comparison of total and bone-specific alkaline phosphatase in patients with nonskeletal disorders or metabolic bone diseases. *Clin Chem* 1996;42:1796-1804.
1147. Robins SP, Duncan A, Wilson N, Evans BJ. Standardization of pyridinium crosslinks, pyridinoline and deoxypyridinoline, for use as biochemical markers of collagen degradation. *Clin Chem* 1996;42:1621-1626.
1150. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. *J Bone Miner Res* 1996;11:835-842.
1151. Garnero P, Borel O, Sornay-Rendu E, Arlot ME, Delmas PD. Vitamin D receptor gene polymorphisms are not related to bone turnover, rate of bone loss, and bone mass in postmenopausal women: The OFELY study. *J Bone Miner Res* 1996;11:827-834.
1152. Berruti A, Piovesan A, Torta M, et al. Biochemical evaluation of bone turnover in cancer patients with bone metastases: Relationship with radiograph appearances and disease extension. *Br J Cancer* 1996;73:1581-1587.
1154. Overgaard K, Alexandersen P, Riis BJ, Christiansen C. Evaluation of a new commercial IRMA for bone-specific alkaline phosphatase during treatment with hormone replacement therapy and calcitonin. *Clin Chem* 1996;42:973-974.
1155. Ono T, Kanzaki S, Seino Y, Baylink DJ, Mohan S. Growth hormone (GH) treatment of GH-deficient children increases serum levels of insulin-like growth factors (IGFs), IGF-binding protein-3 and -5, and bone alkaline phosphatase isoenzyme. *J Clin Endocrinol Metab* 1996;81:2111-2116.
1156. Whyte MP, Walkenhorst DA, Fedde KN, Henthorn PS, Hill CS. Hypophosphatasia: Levels of bone alkaline phosphatase immunoreactivity in serum reflect disease severity. *J Clin Endocrinol Metab* 1996;81:2142-2148.
1157. McKane WR, Khosla S, Egan KS, Robins SP, Burritt MF, Riggs BL. Role of calcium intake in modulating age-related increases in parathyroid function and bone resorption. *J Clin Endocrinol Metab* 1996;81:1699-1703.
1158. Marabini R, Sirtori P, Chionna R, Barzizza L, Rubinacci A. Galactosylhydroxylysine and pyridinium cross links in monitoring the bone response to hormone replacement therapy. *J Endocrinol Invest* 1996;19:154-158.
1159. Garton M, Martin J, New S, et al. Bone mass and metabolism in women aged 45-55. *Clin Endocrinol (Oxf)* 1996;44:563-570.
1160. Gonnelli S, Cepollaro C, Montagnani A, et al. Bone alkaline phosphatase measured with a new immunoradiometric assay in patients with metabolic bone diseases. *Eur J Clin Invest* 1996;26:391-396.
1161. Açil Y, Brinckmann J, Notbohm H, Müller PK, Bätge B. Changes with age in the urinary excretion of hydroxylsilylpyridinoline (HP) and lysylpyridinoline (LP). *Scand J Clin Lab Invest* 1996;56:275-283.
1162. Lems WF, Gerrits MI, Jacobs JWG, van Vugt RM, Van Rijn HJM, Bijlsma JWJ. Changes in (markers of) bone metabolism during high dose corticosteroid pulsetreatment in patients with rheumatoid arthritis. *Ann Rheum Dis* 1996;55:288-293.
1163. Pedrazzoni M, Alfano FS, Girasole G, et al. Clinical observations with a new specific assay for bone alkaline phosphatase: A cross-sectional study in osteoporotic and pagetic subjects and longitudinal evaluation of the response to ovariectomy, estrogens, and bisphosphonates. *Calcif Tissue Int* 1996;59:334-338.
1164. Pepmueller PH, Cassidy JT, Allen SH, Hillman LS. Bone mineralization and bone mineral metabolism in children with juvenile rheumatoid arthritis. *Arthritis Rheum* 1996;39:746-757.
1166. Van Kesteren P, Lips P, Deville W, et al. The effect of one-year cross-sex hormonal treatment on bone metabolism and serum insulin-like growth factor-1 in transsexuals. *J Clin Endocrinol Metab* 1996;81:2227-2232.
1167. Arnala I, Saastamoinen J, Alhava EM. Salmon calcitonin in the prevention of bone loss at perimenopause. *Bone* 1996;18:629-632.
1168. Berruti A, Torta M, Piovesan A, et al. Biochemical picture of bone metabolism in breast cancer patients with bone metastases. *Anticancer Res* 1995;15:2871-2875.
1170. Langdahl BL, Loft AGR, Eriksen EF, Mosekilde L, Charles P. Bone mass, bone turnover and body composition in former hypothyroid patients receiving replacement therapy. *Eur J Endocrinol* 1996;134:702-709.
1171. Nawawi H, Samson D, Apperley J, Girgis S. Biochemical bone markers in patients with multiple myeloma. *Clin Chim Acta* 1996;253:61-77.
1176. Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE. Metabolic effects of pamidronate in patients with metastatic bone disease. *Br J Cancer* 1996;73:1089-1095.
1177. Weaver CM, Peacock M, Martin BR, Plawewski KL, McCabe GP. Calcium retention estimated from indicators of skeletal status in adolescent girls and young women. *Am J Clin Nutr* 1996;64:67-70.
1178. Nyquist F, Ljunghall S, Berglund M, Obrant K. Biochemical markers of bone metabolism after short and long time ethanol withdrawal in alcoholics. *Bone* 1996;19:51-54.
1179. De la Piedra C, Rapado A, Diego EMD, et al. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate. *Calcif Tissue Int* 1996;59:95-99.
1181. Takahashi M, Kushida K, Hoshino H, et al. Concentrations of pyridinoline and deoxypyridinoline in joint tissues from patients with osteoarthritis or rheumatoid arthritis. *Ann Rheum Dis* 1996;55:324-327.

- 1185.Peretz A, Moris M, Willems D, Bergmann P. Is bone alkaline phosphatase an adequate marker of bone metabolism during acute corticosteroid treatment? *Clin Chem* 1996;42:102-103.
- 1186.Perry HM,III, Horowitz M, Morley JE, et al. Aging and bone metabolism in African American and caucasian women. *J Clin Endocrinol Metab* 1996;81:1108-1117.
- 1187.Wiklund T, Blomqvist C, Risteli L, Risteli J, Karaharju E, Elomaa I. Type I and type III collagen metabolites in adult osteosarcoma patients. *Br J Cancer* 1996;73:106-109.
- 1188.Mauras N, Doi SQ, Shapiro JR. Recombinant human insulin-like growth factor I, recombinant human growth hormone, and sex steroids: Effects on markers of bone turnover in humans. *J Clin Endocrinol Metab* 1996;81:2222-2226.
- 1191.Mickelson KE, Casper JM, Tyhach RJ. Development of an assay for urinary deoxypyridinoline for the Technicon Immuno 1® system. *Clin Chem* 1996;42:S110. (abst)
- 1198.Leary ET, Doneen B. Sweat is an alternative non-invasive matrix for measurement of bone loss markers. *Clin Chem* 1996;42:S237. (abst)
- 1203.Cambon P, Graviere C, Ramaoli A, et al. Value of urinary deoxy-pyridinoline assays for detection of bone metastasis in breast cancer patients. *Clin Chem* 1996;42:S251. (abst)
- 1204.Withold W, Arning M, Schwarz M, Wolf H, Schneider W, Reinauer H. Monitoring of therapeutic outcome in patients with multiple myeloma by simultaneously measuring three different biochemical markers of bone metabolism. *Clin Chem* 1996;42:1204. (abst)
- 1215.Hosszu E, Lakatos P, Horvath C, Foldes J. Effect of growth hormone therapy on IGFBP-3 and CIGP levels in children with growth hormone deficiency and Turner's syndrome. *Osteoporosis Int* 1996;6(Suppl.1):179. (abst)
- 1217.Abraha HD, Dolan AL, Pitt PI, Moniz C. Biochemical bone markers reflect early response to treatment in rheumatoid arthritis. *Osteoporosis Int* 1996;6(Suppl.1):183. (abst)
- 1240.Geusens P, Vanhoof J, Nijs J, et al. Heterogeneity of male osteoporosis: Effect of cyclic treatment with etidronate and calcium. *Osteoporosis Int* 1996;6(Suppl.1):285. (abst)
- 1262.Bowles SA, Kurdy N, Davis AM, Marsh D, France MW. Changes in serum bone specific alkaline phosphatase following tibial fracture are not method dependent. *XVI International Congress of Clinical Chemistry, London, UK, July 12-18 1996*; (abst)
- 1265.Walmsley T, Florkowski CM, George PM, et al. Effect of growth hormone on biochemical parameters of bone turnover and bone density in adult hypopituitarism: a six month crossover trial. *XVI International Congress of Clinical Chemistry, London, UK, July 12-18 1996*; (abst)
- 1267.Parviainen MT, Jääskeläinen K, Kröger H, Arnala I, Alhava E. Urinary bone resorption markers in monitoring treatment of symptomatic osteoporosis. *XVI International Congress of Clinical Chemistry, London, UK, July 12-18 1996*; (abst)
- 1284.Laurie D, Barnes AK, Burgess KJ, Duggan RT, Shepard K. A coated tube radioimmunoassay for the measurement of deoxypyridinoline crosslinks in urine. *XVI International Congress of Clinical Chemistry, London, UK, July 12-18 1996*; (abst)
- 1290.Sorva R, Tähtelä R, Turpeinen M, et al. Changes in bone markers in children with asthma during inhaled budesonide and nedocromil treatments. *Acta Paediatr* 1996;85:1176-1180.
- 1291.Lane SJ, Vaja S, Swaminathan R, Lee TH. Effects of prednisolone on bone turnover in patients with corticosteroid resistant asthma. *Clin Exp Allergy* 1996;26:1197-1201.
- 1293.Dresner-Pollak R, Parker RA, Poku M, Thompson J, Seibel MJ, Greenspan SL. Biochemical markers of bone turnover reflect femoral bone loss in elderly women. *Calcif Tissue Int* 1996;59:328-333.
- 1296.Takeuchi SI, Arai K, Saitoh H, Yoshida KI, Miura M. Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer. *J Urol* 1996;156:1691-1695.
- 1297.Yoshida KI, Hosoya Y, Arai K, Sumi S, Honda M. Serum concentration of the pyridinoline crosslinked carboxyterminal telopeptide of type I collagen and urinary concentration of deoxypyridinoline as markers of bone metastases in human prostate carcinoma [letter]. *Clin Chim Acta* 1996;254:93-95.
- 1299.Wang C, Eyre DR, Clark R, et al. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men - A clinical research center study. *J Clin Endocrinol Metab* 1996;81:3654-3662.
- 1300.Guo CY, Thomas WEG, Al-Dehaimi AW, Assiri AMA, Eastell R. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. *J Clin Endocrinol Metab* 1996;81:3487-3491.
- 1304.Matsui H, Yudoh K, Tsuji H. Significance of serum levels of type I procollagen peptide and intact osteocalcin and bone mineral density in patients with ossification of the posterior longitudinal ligaments. *Calcif Tissue Int* 1996;59:397-400.
- 1311.Garnero P, Delmas PD. New developments in biochemical markers for osteoporosis. *Calcif Tissue Int* 1996;59(Suppl.):S2-S9.
- 1317.Tobias JH, Laversuch CV, Wilson N, Robins SP. Neridronate preferentially suppresses the urinary excretion of peptide-bound deoxypyridinoline in postmenopausal women. *Calcif Tissue Int* 1996;59:407-409.
- 1318.Garnero P, Delmas PD. Measurements of biochemical markers: methods and limitations. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of bone biology. San Diego: Academic Press, 1996:1277-1291.
- 1319.Prestwood KM, Pannullo AM, Kenny AM, Pilbeam CC, Raisz LG. The effect of a short course of calcium and Vitamin D on bone turnover in older women. *Osteoporosis Int* 1996;6:314-319.
- 1320.Leino A, Impivaara O, Kaitsaari M. Measurements of deoxypyridinoline and hydroxyproline in 24-h, first morning, and second morning urine samples. *Clin Chem* 1996;42:2037-2039.
- 1322.Tsai KS, Hsu SHJ, Cheng WC, Chen CK, Chieng PU, Pan WH. Bone mineral density and bone markers in relation to Vitamin D receptor gene polymorphisms in Chinese men and women. *Bone* 1996;19:513-518.
- 1323.Ravn P, Clemmesen B, Riis BJ, Christiansen C. The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding study. *Bone* 1996;19:527-533.
- 1324.Langdahl BL, Loft AG, Moller N, et al. Skeletal responsiveness to thyroid hormone is not altered at menopause. *Bone* 1996;19:557-564.
- 1328.Brixen K, Kassem M, Nielsen HK, Loft AG, Flyvbjerg A, Mosekilde L. Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: A dose response study. *J Bone Miner Res* 1996;10:1865-1874.
- 1329.Dure-Smith BA, Farley SM, Linkhart SG, Farley JR, Baylink DJ. Calcium deficiency in fluoride-treated osteoporotic patients despite calcium supplementation. *J Clin Endocrinol Metab* 1996;81:269-275.
- 1330.Pecherstorfer M, Ludwig H, Schlosser K, Buck S, Huss H, Body JJ. Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. *J Bone Miner Res* 1996;11:587-593.
- 1336.Guerrero R, Diaz Martin MA, Diaz Diego EM, Disla T, Rapado A, De la Piedra C. New biochemical markers of bone resorption derived from collagen breakdown in the study of postmenopausal osteoporosis. *Osteoporosis Int* 1996;6:297-302.
- 1344.Simberg N, Tiitinen A, Silfvast A, Viinikka L, Ylikorkala O. High bone density in hyperandrogenic women: Effect of gonadotropin-releasing hormone agonist alone or in conjunction with estrogen-progestin replacement. *J Clin Endocrinol Metab* 1996;81:646-651.
- 1345.Coleman RE, Houston S, James I, et al. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease. *Br J Cancer* 1992;65:766-768.

1346. Cooper EH, Forbes MA, Hancock AK, Parker D, Laurence V. Serum bone alkaline phosphatase and CA 549 in breast cancer with bone metastases. *Biomed and Pharmacother* 1992;46:31-36.
1347. Stieber P, Ritzke C, Rössler N, et al. Significance of bone alkaline phosphatase, CA-15-3 and CEA in the detection of bone metastases during the follow-up of patients suffering from breast carcinoma. *Eur J Clin Chem Clin Biochem* 1992;30:809-814.
1348. Akimoto S, Akakura K, Shimazaki J. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer. *Jpn J Clin Oncol* 1996;26:157-163.
1350. Withold W, Degenhardt S, Heins M, Grabensee B, Reinauer H. Monitoring of bone resorption after renal transplantation by measuring the urinary excretion of pyridinium cross-links. *Eur J Clin Chem Clin Biochem* 1995;33:15-21.
1353. Kohlmeier L, Gasner C, Bachrach LK, Marcus R. The bone mineral status of patients with Marfan syndrome. *J Bone Miner Res* 1995;10:1550-1555.
1355. Bowles SA, Kurdy N, Davis AM, France MW, Marsh DR. Serum osteocalcin, total and bone-specific alkaline phosphatase following isolated tibial shaft fracture. *Ann Clin Biochem* 1996;33:196-200.
1357. Bjarnason NH, Bjarnason K, Haarbo J, Rosequist C, Christiansen C. Tibolone: Prevention of bone loss in late postmenopausal women. *J Clin Endocrinol Metab* 1996;81:2419-2422.
1360. Johannsson G, Rosén T, Bosaeus I. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. *J Clin Endocrinol Metab* 1996;81:2865-2873.
1362. Müller A, Hein G, Franke S, et al. Quantitative analysis of pyridinium crosslinks of collagen in the synovial fluid of patients with rheumatoid arthritis using high-performance liquid chromatography. *Rheumatol Int* 1996;16:23-28.
1365. Sharp CA, Davie MWJ, Worsfold M, Risteli L, Risteli J. Discrepant blood concentrations of type I procollagen propeptides in active Paget disease of bone. *Clin Chem* 1996;42:1121-1122.
1384. Tommasi M, Bacciottini L, Benucci A, et al. Serum biochemical markers of bone turnover in healthy infants and children. *Int J Biol Markers* 1996;11:159-164.
1385. Ureña P, Prieur PH, Pétrou M. Bone-specific alkaline phosphatase in hemodialysis patients. *Presse Med* 1996;25:1320-1325.
1388. Lakatos P, Kiss L, Horvath C, et al. Effect of alphacalcidol on bone in patients treated with glucocorticoids. *J Bone Miner Res* 1996;11(Suppl.):S226. (abst)
1390. Garcia Delgado I, Hawkins F, Gilgragues L, et al. Bone markers and bone mass in patients with cardiac transplant with antiresorptive drugs. *J Bone Miner Res* 1996;11(Suppl.):S340. (abst)
1391. Takacs I, Kiss L, Horvath C, Foldes J, Lakatos P, Tarjan G. Serum levels of type I collagen carboxyterminal propeptide and bone metabolism in hyperthyroidism. *J Bone Miner Res* 1996;11(Suppl.):S441 (abst)
1396. Hannon RA, Blumsohn A, Wrate RM, Barton J, Eastell R. Longitudinal changes in bone turnover in girls during puberty. *J Bone Miner Res* 1996;11(Suppl.):S468. (abst)
1397. Takahashi S, Koizumi M, Aiba K, Horikoshi N, Ogata E. Efficacy of biochemical markers of bone metabolism to detect and follow bone metastases of breast cancer. *J Bone Miner Res* 1996;11(Suppl.):S482. (abst)
1400. Kraenzlin ME, Kraenzlin CA, Haas HG. Bone formation and resorption dynamics during and after fluoride therapy in osteoporosis. *J Bone Miner Res* 1996;11(Suppl.):S133. (abst)
1407. Cummings SR, Black D, Ensrud K, et al. Urine markers of bone resorption predict hip bone loss and fractures in older women: The Study of Osteoporotic Fractures. *J Bone Miner Res* 1996;11(Suppl.):S128. (abst)
1412. Okazaki R, Totsuka Y, Ajima M, et al. Metabolic improvement of non-insulin dependent diabetes mellitus reduces bone turnover. *J Bone Miner Res* 1996;11(Suppl.):S438. (abst)
1413. Suzuki M, Takahashi M, Kushida K, et al. Assessment of bone metabolism by biochemical markers in patients with rheumatoid arthritis. *J Bone Miner Res* 1996;11(Suppl.):S440. (abst)
1418. Cosman F, Nieves I, Sherwood D, Shen V, Lindsay R. Comparative effects of tissue selective estrogens and estrogen on bone mineral density and bone turnover. *J Bone Miner Res* 1996;11(Suppl.):S450. (abst)
1422. Shane E, Thys-Jacobs W, Papdopoulos A, et al. Antiresorptive therapy prevents bone loss after cardiac transplantation (CTX). *J Bone Miner Res* 1996;11(Suppl.):S340. (abst)
1424. Kawana K, Wilson N, Inoue T, et al. Racial differences in urinary pyridinium crosslink excretion. *J Bone Miner Res* 1996;11(Suppl.):S193. (abst)
1428. Giannini S, D'Angelo A, Sartori L, et al. Metabolic bone disease in renal transplantation recipients. *J Bone Miner Res* 1996;11(Suppl.):S127. (abst)
1431. Morii H, Orimo H, Taketani Y, et al. Effect of raloxifene hydrochloride on postmenopausal Japanese women with osteoporosis. *J Bone Miner Res* 1996;11(Suppl.):S446. (abst)
1432. Price C, Milligan T, Darte C. Evidence for different isoforms of bone alkaline phosphatase in children and Paget's disease: Observations based on the relative accuracy of immunoassays. *J Bone Miner Res* 1996;11(Suppl.):S368. (abst)
1434. Colwell A, Eastell R. The renal clearance of free and conjugated pyridinium cross-links of collagen. *J Bone Miner Res* 1996;11:1976-1980.
1438. Shane E, Rivas M, Staron RB, et al. Fracture after cardiac transplantation: A prospective longitudinal study. *J Clin Endocrinol Metab* 1996;81:1740-1746.
1443. James IT, Walne AJ, Perrett D. The measurement of pyridinium crosslinks: a methodological overview. *Ann Clin Biochem* 1996;33:397-420.
1444. Pereira RMR, Corrente JE, Chahade W, Cossermelli W. Levels of deoxypyridinoline crosslinks in healthy children and children with juvenile rheumatoid arthritis (JRA). *Arthritis Rheum* 1996;39:S55. (abst)
1445. Lane NE, Thompson JM, Modin G, Sanchez S, Arnaud C. Can parathyroid hormone treatment reverse steroid osteoporosis: Preliminary results of biochemical markers and bone density. *Arthritis Rheum* 1996;39:S217. (abst)
1446. Eastell R, Colwell A, Hampton L, Reeve J. Biochemical markers of bone resorption compared with estimates of bone resorption from radiotracer kinetic studies in Osteoporosis. *J Bone Miner Res* 1997;12:59-65.
1447. Marcocci C, Golia F, Vignali E, Pinchera A. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine. *J Bone Miner Res* 1997;12:72-77.
1448. Langdahl BL, Loft AG, Moller N, et al. Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement? *J Bone Miner Res* 1997;12:78-88.
1449. Heikkinen JE, Selander KS, Laitinen K, Arnala I, Väänänen HK. Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss. *J Bone Miner Res* 1997;12:103-110.
1452. Facon T, Mary JY, Daneshpouy M, Faucompré JL, Hennache B. Evaluation of urinary deoxypyridinoline in patients with monoclonal gammopathy of undetermined significance and multiple myeloma. *Blood* 1996;88:387a. (abst)
1453. Papapoulos SE, Frölich M. Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption. *J Clin Endocrinol Metab* 1996;81:3993-3997.
1456. Bone H, Downs RW, Jr., Tucci J, et al. Dose-response relationships for alendronate treatment in osteoporotic elderly women. *J Clin Endocrinol Metab* 1997;82:265-274.

1462. Consensus Development Statement . Who are candidates for prevention and treatment for osteoporosis? *Osteoporosis Int* 1997;7:1-6.
1464. Cannon R, Ju J, Arnaud C. Analytical and biological variability of three bone resorption markers affect interpretation of alendronate response. *Bone* 1997;4:49S. (abst)
1465. Shepard K, Jenkins D. Bone-specific alkaline phosphatase truly reflects increased bone turnover in postmenopausal women. *Bone* 1997;4:54S. (abst)
1466. Ross PD, Jenkins D. Prediction of rapid bone loss during 13 years followup using biochemical bone markers. *Bone* 1997;4:6S. (abst)
1472. Schlemmer A, Hassager C, Delmas PD, Christiansen C. Urinary excretion of pyridinium cross-links in healthy women; the long-term effects of menopause and oestrogen/progesterone therapy. *Clin Endocrinol (Oxf)* 1994;40:777-782.
1473. Siddiqui A, Burrin JM, Noonan K, et al. A longitudinal study of markers of bone turnover in Graves' disease and their value in predicting bone mineral density. *J Clin Endocrinol Metab* 1997;82:753-759.
1474. Noonan K, Kalu ME, Holownia P, Burrin JM. Effect of different storage temperatures, sample collection procedures and immunoassay methods on osteocalcin measurement. *Eur J Clin Chem Clin Biochem* 1997;34:841-844.
1475. Morote J, Lorente JA, Encabo G. Prostate carcinoma staging: Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen. *Cancer* 1996;78:2374-2378.
1476. Maeda H, Koizumi M, Yoshimura K, Yamauchi T, Kawai T, Ogata E. Correlation between bone metabolic markers and bone scan in prostatic cancer. *J Urol* 1997;157:539-543.
1477. Gonnelli S, Cepollaro C, Pondrelli C, Martini S, Monaco R, Gennari C. The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis. *J Bone Miner Res* 1997;12:624-631.
1481. Magnusson P, Degerblad M, Sääf M, Larsson L, Thorén M. Different responses of bone alkaline phosphatase isoforms during recombinant insulin-like growth factor-I (IGF-I) and during growth hormone therapy in adults with growth hormone deficiency. *J Bone Miner Res* 1997;12:210-220.
1482. McClure L, Eccleshall TR, Gross C, et al. Vitamin D receptor polymorphisms, bone mineral density, and bone metabolism in postmenopausal Mexican-American women. *J Bone Miner Res* 1997;12:234-240.
1485. Hsu SHJ, Tsai KS. Different age-related trends of bone and nonbone forms of alkaline phosphatase in Chinese men and women. *Clin Chem* 1997;43:186-188.
1491. Garcia-Delgado I, Prieto S, Gil-Fraguas L, Robles E, Ruffinanchas JJ, Hawkins F. Calcitonin, etidronate, and calcidiol treatment in bone loss after cardiac transplantation. *Calcif Tissue Int* 1997;60:155-159.
1492. Sairanen S, Tähtelä R, Laitinen K, Löyttyniemi E, Välimäki MJ. Effects of short-term treatment with clodronate on parameters of bone metabolism and their diurnal variation. *Calcif Tissue Int* 1997;60:160-163.
1493. Brahm H, Piehl-Aulin K, Saltin B, Ljunghall S. Net fluxes over working thigh of hormones, growth factors and biomarkers of bone metabolism during short lasting dynamic exercise. *Calcif Tissue Int* 1997;60:175-180.
1497. Vihervuori E, Turpeinen M, Siimes MA, Koistinen H, Sorva R. Collagen formation and degradation increase during growth hormone therapy in children. *Bone* 1997;20:133-138.
1501. Khan SA, Vasikaran S, McCloskey EV, et al. Alendronate in the treatment of Paget's disease of bone. *Bone* 1997;20:263-271.
1503. Langdahl BL, Knudsen JY, Jensen HK, Gregersen N, Eriksen EF. A sequence variation: 713-8delC in the transforming growth factor-beta 1 gene has higher prevalence in osteoporotic women than in normal women and is associated with very low bone mass in osteoporotic women and increased bone turnover in both osteoporotic and normal women. *Bone* 1997;20:289-294.
1504. Lakatos P, Foldes J, Horvath C, et al. Serum interleukin-6 and bone metabolism in patients with thyroid function disorders. *J Clin Endocrinol Metab* 1997;82:78-81.
1507. Prince RL, Dick I, Lemmon J, Randell D. The pathogenesis of age-related osteoporotic fracture: Effects of dietary calcium deprivation. *J Clin Endocrinol Metab* 1997;82:260-264.
1508. Hodsmann AB, Fraher LJ, Watson PH, et al. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. *J Clin Endocrinol Metab* 1997;82:620-628.
1509. Guo CY, Jones TH, Eastell R. Treatment of isolated hypogonadotropic hypogonadism effect on bone mineral density and bone turnover. *J Clin Endocrinol Metab* 1997;82:658-665.
1510. Ettinger B, Sidney S, Cummings SR, et al. Racial differences in bone density between young adult black and white subjects persist after adjustment for anthropometric, lifestyle, and biochemical differences. *J Clin Endocrinol Metab* 1997;82:429-434.
1511. Burman P, Johansson AG, Siegbahn A, Vessby B, Karlsson FA. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy. *J Clin Endocrinol Metab* 1997;82:550-555.
1512. Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. *J Clin Oncol* 1997;15:131-138.
1513. Crofton PM, Stirling HF, Schönau E, Kelnar CJH. Bone alkaline phosphatase and collagen markers as early predictors of height velocity response to growth-promoting treatments in short normal children. *Clin Endocrinol (Oxf)* 1996;44:385-394.
1514. Crofton PM, Stirling HF, Schönau E, et al. Biochemical markers of bone turnover. *Horm Res* 1996;45 Suppl. 1:55-58.
1515. Gross C, Eccleshall TR, Malloy PJ, Villa ML, Marcus R, Feldman D. The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women. *J Bone Miner Res* 1996;11:1850-1855.
1516. Wada S, Katayama Y, Yasutomo Y, Kugai N, Nagata N. Changes of bone metabolic markers in patients with bone metastases. *Intern Med* 1993;32:611-618.
1518. Jennings BH, Andersson KE, Johansson SA. Assessment of systemic effects of inhaled glucocorticosteroids: A comparison of the effect of inhaled budesonide and oral prednisolone on adrenal function and markers of bone turnover. *Eur J Clin Pharmacol* 1991;40:77-82.
1519. Sorva R, Turpeinen M, Juntunen-Backman K, Karonen SL, Sorva A. Effects of inhaled budesonide on serum markers of bone metabolism in children with asthma. *J Allergy Clin Immunol* 1992;90:808-815.
1520. Demiaux B, Arlot ME, Chapuy M-C, Meunier PJ, Delmas PD. Serum osteocalcin is increased in patients with osteomalacia: correlations with biochemical and histomorphometric findings. *J Clin Endocrinol Metab* 1992;74:1146-1151.
1521. Orimo H, Shiraki M, Inoue S. Estrogen and bone. *Osteoporosis Int* 1993;Suppl.:S153-S156.
1522. Crofton PM, Stirling HF, Schönau E, et al. Collagen markers and bone alkaline phosphatase as predictors of bone turnover and growth. *Paediatric osteology: New developments in diagnostics and therapy* 1996;241-250.
1523. Keaveny AP, Freaney R, McKenna MJ, Masterson J, O'Donoghue DP. Bone remodeling indices and secondary hyperparathyroidism in celiac disease. *Am J Gastroenterol* 1996;91:1226-1231.
1524. James IT, Walne AJ, Perrett D. Automated solid-phase extraction with high-performance liquid chromatography analysis of pyridinium crosslinks. *Anal Biochem* 1996;240:29-36.
1525. Zaninotto M, Secchiero S, Rubin D, et al. Serum bone alkaline phosphatase in the follow-up of skeletal metastases. *Anticancer Res* 1995;15:2223-2228.

1526. Cecchetti M, Bellometti S, Cremonesi G, Solimeno LP, Torri G. Metabolic and bone effects after administration of ipriflavone and salmon calcitonin in postmenopausal osteoporosis. *Biomed Pharmacother* 1995;49:465-468.
1527. Ureña P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. *J Am Soc Nephrol* 1996;7:506-512.
1528. Liu PPL, Leung KS, Kumta SM, Lee KM, Fung KP. Bone-specific alkaline phosphatase in plasma as tumour marker for osteosarcoma. *Oncology* 1996;53:275-280.
1530. Hayasaka A, Iida S, Suzuki N, Kondo F, Miyazaki M, Yonemitsu H. Pyridinoline collagen cross-links in patients with chronic viral hepatitis and cirrhosis. *J Hepatol* 1996;24:692-698.
1531. Beyeler C, Banks R, Thompson D, Forbes MA, Cooper EH, Bird HA. Bone alkaline phosphatase in rheumatoid arthritis: A longitudinal study. *J Rheumatol* 1996;23:241-244.
1532. Iki M, Kajita E, Dohi Y, et al. Age, menopause, bone turnover markers and lumbar bone loss in healthy Japanese women. *Maturitas* 1996;25:59-67.
1533. Hansen TB, Brixen K, Vahl N, et al. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: A double blind, randomized, placebo-controlled study. *J Clin Endocrinol Metab* 1996;81:3352-3359.
1534. Ohishi T, Kushida K, Takahashi M, Kawana K, Inoue T, Yagi K. Analysis of urinary pyridinoline and deoxypyridinoline in patients undergoing long-term anticonvulsant drug therapy. *Eur Neurol* 1996;36:300-302.
1535. Chapuy MC, Schott AM, Garnero P, et al. Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter. *J Clin Endocrinol Metab* 1996;81:1129-1133.
1536. Douglas AS, Miller MH, Reid DM, Hutchison JD, Porter RW, Robins SP. Seasonal differences in biochemical parameters of bone remodelling. *J Clin Pathol* 1996;49:284-289.
1537. Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC, III. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. *Am J Med* 1996;101:488-501.
1538. Tsai KS, Pan WH, Hsu SHJ, et al. Sexual differences in bone markers and bone mineral density of normal Chinese. *Calcif Tissue Int* 1996;59:454-460.
1539. Wolff JM, Ittel T, Boeckmann W, Reinike T, Habib FK, Jakse G. Skeletal alkaline phosphatase in the metastatic: Workup of patients with prostate cancer. *Eur Urol* 1996;30:302-306.
1540. Peest D, Deicher H, Fett W, et al. Pyridinium cross-links in multiple myeloma: Correlation with clinical parameters and use for monitoring of intravenous clodronate therapy - A pilot study of the German Myeloma Treatment Group (GMTG). *Eur J Cancer [A]* 1996;32A:2053-2057.
1541. Gonnelli S, Cepollaro C, Montomoli M, et al. Treatment of post-menopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: A placebo controlled study. *Clin Endocrinol (Oxf)* 1997;46:55-61.
1542. Rauch F, Rauch R, Woitge HW, Seibel MJ, Schönau E. Urinary immunoreactive deoxypyridinoline in children and adolescents: Variations with age, sex and growth velocity. *Scand J Clin Lab Invest* 1996;56:715-719.
1543. Knapen MHJ, Eisenwiener HG, Vermeer C. Osteocalcin detection in aging serum and whole blood: Stability of different osteocalcin fractions. *Clin Chim Acta* 1996;256:151-164.
1544. Rubinacci A, Divieti P, Polo RM, Zampino M, Resmini G, Tenni R. Effect of an oral calcium load on urinary markers of collagen breakdown. *J Endocrinol Invest* 1996;19:719-726.
1545. Body JJ, Dumon JC, Gineyts E, Delmas PD. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. *Br J Cancer* 1997;75:408-412.
1546. Colwell A, Hamer A, Blumsohn A, Eastell R. To determine the effects of ultraviolet light, natural light and ionizing radiation on pyridinium cross-links in bone and urine using high-performance liquid chromatography. *Eur J Clin Invest* 1996;26:1107-1114.
1548. Thorsen K, Kristoffersson A, Hultdin J, Lorentzon R. Effects of moderate endurance exercise on calcium, parathyroid hormone, and markers of bone metabolism in young women. *Calcif Tissue Int* 1997;60:16-20.
1558. Bonfanti R, Mora S, Prinster C, et al. Bone modeling indexes at onset and during the first year of follow-up in insulin-dependent diabetic children. *Calcif Tissue Int* 1997;60:397-400.
1560. Greenspan SL, Dresner-Pollak R, Parker RA, London D, Ferguson L. Diurnal variation of bone mineral turnover in elderly men and women. *Calcif Tissue Int* 1997;60:419-423.
1561. Erben RG, Bante U, Birner H, Stangassinger M. Prophylactic effects of 1,24,25-trihydroxyvitamin D₃ on ovariectomy-induced cancellous bone loss in the rat. *Calcif Tissue Int* 1997;60:434-440.
1562. Erben RG, Bante U, Birner H, Stangassinger M. 1 α -hydroxyvitamin D₂ partially dissociates between preservation of cancellous bone mass and effects on calcium homeostasis in ovariectomized rats. *Calcif Tissue Int* 1997;60:449-456.
1563. Svanberg M, Mattila P, Knuutila M. Dietary xylitol retards the ovariectomy-induced increase of bone turnover in rats. *Calcif Tissue Int* 1997;60:462-466.
1564. Jerome CP, Power RA, Obasanjo IO, et al. The androgenic anabolic steroid nandrolone decanoate prevents osteopenia and inhibits bone turnover in ovariectomized cynomolgus monkeys. *Bone* 1997;20:355-364.
1565. Tsai KS, Hsu SHJ, Cheng JP, Yang RS. Vitamin D stores of urban women in Taipei: Effect on bone density and bone turnover, and seasonal variation. *Bone* 1997;20:371-374.
1566. Han ZH, Palnitkar S, Rao DS, Nelson D, Parfitt AM. Effects of ethnicity and age or menopause on the remodeling and turnover of iliac bone: Implications for mechanisms of bone loss. *J Bone Miner Res* 1997;12:498-508.
1567. Fujimura R, Ashizawa N, Watanabe M, et al. Effect of resistance exercise training on bone formation and resorption in young male subjects assessed by biomarkers of bone metabolism. *J Bone Miner Res* 1997;12:656-662.
1568. Slemenda CW, Peacock M, Hui S, Zhou LF, Johnston CC. Reduced rates of skeletal remodeling are associated with increased bone mineral density during the development of peak skeletal mass. *J Bone Miner Res* 1997;12:676-682.
1572. Anderson FH, Francis RM, Peaston RT, Wastell HJ. Androgen supplementation in eugonadal men with osteoporosis: Effects of six months' treatment on markers of bone formation and resorption. *J Bone Miner Res* 1997;12:472-478.
1573. Ju HJ, Leung S, Brown B, Stringer MA, Leigh S, Scherrer C, Sherpard K, Jenkins D, Knudsen J, Canon R. Comparison of analytical and biological variability of three bone resorption assays. *Clin Chem* 1997;(in press)
1574. Cioffi M, Molinari AM, Gazzero P, et al. Serum osteocalcin in 1634 healthy children. *Clin Chem* 1997;43:543-545.
1575. Bennell KL, Malcolm SA, Khan KM, et al. Bone mass and bone turnover in power athletes, endurance athletes, and controls: A 12-month longitudinal study. *Bone* 1997;20:477-484.
1576. Vergnaud P, Garnero P, Meunier PJ, Bréart G, Kamihagi K, Delmas PD. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: The EPIDOS study. *J Clin Endocrinol Metab* 1997;82:719-724.
1579. Batmann A, Resch H, Libanati CR, et al. Serum fluoride and serum osteocalcin levels in response to a novel sustained-release monofluorophosphate preparation: Comparison with plain monofluorophosphate. *Osteoporosis Int* 1997;7:48-51.

- 1580.Holloway L, Kohlmeier L, Kent K, Marcus R. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women. *J Clin Endocrinol Metab* 1997;82:1111-1117.
- 1581.Han KO, Moon IG, Kang YS, Chung HY, Min HK, Han IK. Nonassociation of estrogen receptor genotypes with bone mineral density and estrogen responsiveness to hormone replacement therapy in Korean postmenopausal women. *J Clin Endocrinol Metab* 1997;82:991-995.